Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 569 articles:
HTML format



Single Articles


    February 2025
  1. SUN Y, Liu N, Liu Y, Deng J, et al
    Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement.
    Leuk Lymphoma. 2025 Feb 10:1-4. doi: 10.1080/10428194.2025.2460046.
    PubMed    


  2. THOMAS CJ, Porter D, Van Deerlin VM, Bhattacharyya S, et al
    Aleukemic soft-tissue relapse post allogeneic hematopoietic cell transplantation in T-prolymphocytic leukemia.
    Leuk Lymphoma. 2025 Feb 8:1-4. doi: 10.1080/10428194.2025.2462950.
    PubMed    


  3. LANG F, Voss A, Kobbe G, Junghanss C, et al
    Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Feb 8:1-9. doi: 10.1080/10428194.2025.2460737.
    PubMed     Abstract available


  4. CHIN KK, Derkach A, Famulare C, Gupta GK, et al
    HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.
    Leuk Lymphoma. 2025;66:270-278.
    PubMed     Abstract available


    January 2025
  5. KRSTEVSKA BOZHINOVIKJ E, Matevska-Geshkovska N, Staninova Stojovska M, Gjorgievska E, et al
    Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 22:1-8. doi: 10.1080/10428194.2025.2456100.
    PubMed     Abstract available


  6. JEONG Y
    Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutations and higher mutation burden in myeloproliferative CMML compared to myelodysplastic CMML.
    Leuk Lymphoma. 2025 Jan 17:1-10. doi: 10.1080/10428194.2025.2453093.
    PubMed     Abstract available


  7. TESSIER S, McCullough KB, Gangat N, Begna KH, et al
    Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 16:1-5. doi: 10.1080/10428194.2024.2443017.
    PubMed    


  8. HEILBRONNER AK, Blumberg O, Krez A, McMahon DJ, et al
    High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 15:1-4. doi: 10.1080/10428194.2025.2452340.
    PubMed    


  9. ZHU H, Zhang C, Huang L, Zhang B, et al
    Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm.
    Leuk Lymphoma. 2025 Jan 15:1-12. doi: 10.1080/10428194.2025.2451064.
    PubMed     Abstract available


  10. LI M, Zhao DQ, Kong XY, Wang SM, et al
    Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 11:1-11. doi: 10.1080/10428194.2025.2451059.
    PubMed     Abstract available


  11. SENAPATI J, Kantarjian H, Habib D, Haddad FG, et al
    Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.
    Leuk Lymphoma. 2025 Jan 10:1-12. doi: 10.1080/10428194.2025.2449582.
    PubMed     Abstract available


  12. ZHANG F, Liu Y, Zhu Y, Wang Q, et al
    Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia.
    Leuk Lymphoma. 2025 Jan 2:1-11. doi: 10.1080/10428194.2024.2441855.
    PubMed     Abstract available


  13. YSEBAERT L, Mouchel PL, Laurent C, Quillet-Mary A, et al
    The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2025 Jan 2:1-13. doi: 10.1080/10428194.2024.2447362.
    PubMed     Abstract available


    December 2024
  14. AVGERINOU G, Solomou EE, Filippidou M, Perganti F, et al
    Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia.
    Leuk Lymphoma. 2024 Dec 28:1-4. doi: 10.1080/10428194.2024.2445701.
    PubMed    


  15. GUGLIELMANA V, Rossi D
    Prognostic and predictive impact of NOTCH1 mutation in chronic lymphocytic leukemia: a systematic review.
    Leuk Lymphoma. 2024 Dec 27:1-10. doi: 10.1080/10428194.2024.2441858.
    PubMed     Abstract available


  16. NILSSON MS, Martner A, Wennstrom L, Hansson M, et al
    Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Dec 24:1-3. doi: 10.1080/10428194.2024.2444466.
    PubMed    


  17. DAMPMANN M, Kibler A, von Tresckow J, Reinhardt HC, et al
    Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern.
    Leuk Lymphoma. 2024 Dec 17:1-9. doi: 10.1080/10428194.2024.2438804.
    PubMed     Abstract available


  18. OLIAI C, Park S, Damon LE, Jonas BA, et al
    CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
    Leuk Lymphoma. 2024 Dec 17:1-7. doi: 10.1080/10428194.2024.2438809.
    PubMed     Abstract available


  19. SHELLEY CS, Galiegue-Zouitina S, Andritsos LA, Epperla N, et al
    The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease.
    Leuk Lymphoma. 2024 Dec 17:1-19. doi: 10.1080/10428194.2024.2438800.
    PubMed     Abstract available


  20. ISHIKAWA C, Mori N
    ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia.
    Leuk Lymphoma. 2024 Dec 17:1-12. doi: 10.1080/10428194.2024.2441875.
    PubMed     Abstract available


  21. KOVACH AE, Komova D, Itov A, Gaskova M, et al
    Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype.
    Leuk Lymphoma. 2024;65:1840-1852.
    PubMed     Abstract available


  22. MINA A
    Targeted therapy in acute T-cell leukemia/lymphoma: are we close?
    Leuk Lymphoma. 2024 Dec 1:1-3. doi: 10.1080/10428194.2024.2432575.
    PubMed    


  23. PAISIOU A, OIkonomopoulou C, Pavlidis D, Ampatzidou M, et al
    CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2434177.
    PubMed    


  24. RIOS-OLAIS FA, Rodriguez-Rodriguez S, Mora-Canas A, Ramos-Penafiel CO, et al
    Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2432582.
    PubMed    


  25. EHRMANN AS, Zadro A, Tausch E, Schneider C, et al
    The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL.
    Leuk Lymphoma. 2024;65:1941-1953.
    PubMed     Abstract available


  26. ARAD-COHEN N, Messinger Y, Barzilai-Birenboim S, Ben-Harosh M, et al
    National study reveals gram negative bacteremia on contemporary pediatric AML protocol.
    Leuk Lymphoma. 2024;65:1991-1999.
    PubMed     Abstract available


  27. TASHAKORI M, Yohe S, Linden MA, McKenna RW, et al
    The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the Minnesota experience.
    Leuk Lymphoma. 2024;65:2151-2162.
    PubMed     Abstract available


  28. BOHN JP, Stolzlechner V, Gobel G, Pirklbauer M, et al
    Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function.
    Leuk Lymphoma. 2024;65:2108-2115.
    PubMed     Abstract available


    November 2024
  29. PAUL S, Jabbour E, Nichols ED, Short NJ, et al
    Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes.
    Leuk Lymphoma. 2024 Nov 29:1-11. doi: 10.1080/10428194.2024.2426052.
    PubMed     Abstract available


  30. SHORT NJ, Wierzbowska A, Cluzeau T, Laribi K, et al
    Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 28:1-11. doi: 10.1080/10428194.2024.2431878.
    PubMed     Abstract available


  31. MIMS A, Xie Z, Potluri R, Rotter D, et al
    Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 28:1-9. doi: 10.1080/10428194.2024.2425792.
    PubMed     Abstract available


  32. COSTA A, Scalzulli E, Carmosino I, Ielo C, et al
    Clinical and biological advances of critical complications in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 24:1-20. doi: 10.1080/10428194.2024.2425051.
    PubMed     Abstract available


  33. ARRIGO G, Scaldaferri M, Audisio E, Boscaro E, et al
    Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.
    Leuk Lymphoma. 2024 Nov 8:1-2. doi: 10.1080/10428194.2024.2427266.
    PubMed    


  34. KORSHOLM C, Bulow C, Christensen M, Dalhoff K, et al
    Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review.
    Leuk Lymphoma. 2024 Nov 7:1-11. doi: 10.1080/10428194.2024.2412289.
    PubMed     Abstract available


  35. LECORNEC N, Duchmann M, Itzykson R
    Single-cell sequencing applications in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 4:1-15. doi: 10.1080/10428194.2024.2422833.
    PubMed     Abstract available


  36. TAM C, Zhao FL, Azam S, Li SC, et al
    Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset.
    Leuk Lymphoma. 2024;65:1576-1585.
    PubMed     Abstract available


    October 2024
  37. THARAKAN S, Tremblay D, Azzi J
    Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies.
    Leuk Lymphoma. 2024 Oct 25:1-14. doi: 10.1080/10428194.2024.2414112.
    PubMed     Abstract available


  38. ROTTER LK, Alhajahjeh A, Stempel JM, Grimshaw AA, et al
    Analyzing determinants of premature trial discontinuation in leukemia clinical trials.
    Leuk Lymphoma. 2024 Oct 23:1-9. doi: 10.1080/10428194.2024.2416565.
    PubMed     Abstract available


  39. KIM SA, Jung M, Kim H, Byun JM, et al
    MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.
    Leuk Lymphoma. 2024 Oct 22:1-8. doi: 10.1080/10428194.2024.2414903.
    PubMed     Abstract available


  40. DEHGHANI SS, Wang Y, Ramesh KH, Cooper D, et al
    Atypical chronic myeloid leukemia (CML) with ETV6-ABL1 mutation managed successfully with a third-generation TKI and hematopoietic stem cell transplant.
    Leuk Lymphoma. 2024 Oct 18:1-3. doi: 10.1080/10428194.2024.2403666.
    PubMed    


  41. RIBERA JM, Torrent A
    Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Oct 18:1-11. doi: 10.1080/10428194.2024.2416569.
    PubMed     Abstract available


  42. KANKARIA RA, Jones JB, Zargari M, Alexander DW, et al
    Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax.
    Leuk Lymphoma. 2024 Oct 16:1-4. doi: 10.1080/10428194.2024.2416573.
    PubMed    


  43. MOHAMMAD EM, El-Ayadi M, Kamel A, Ebeid E, et al
    Early impact of treatment modifications adopted for acute lymphoblastic leukemia during SARS-CoV-2 pandemic; a single center experience and lessons for LMICs.
    Leuk Lymphoma. 2024 Oct 9:1-7. doi: 10.1080/10428194.2024.2411432.
    PubMed     Abstract available


  44. SHANG Q, Wang Y, Lu A, Jia Y, et al
    Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.
    Leuk Lymphoma. 2024 Oct 8:1-10. doi: 10.1080/10428194.2024.2406958.
    PubMed     Abstract available


  45. BRUNER SA, DiPippo AJ, Rausch CR
    Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia: experience of a tertiary cancer care center.
    Leuk Lymphoma. 2024 Oct 7:1-3. doi: 10.1080/10428194.2024.2411626.
    PubMed    


  46. SHADMAN M, Salkar M, Srivastava B, Karve S, et al
    Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Oct 1:1-10. doi: 10.1080/10428194.2024.2402814.
    PubMed     Abstract available


    September 2024
  47. ZABLONSKI KG, Skupa SA, Eiken AP, Sundaram S, et al
    Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Sep 27:1-9. doi: 10.1080/10428194.2024.2398663.
    PubMed     Abstract available


  48. SHANGGUAN X, Huang Y, Chen C, Wu W, et al
    Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2024 Sep 23:1-12. doi: 10.1080/10428194.2024.2404957.
    PubMed     Abstract available


  49. KOPMAR NE, Qu X, Liu Y, Gooley TA, et al
    Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Sep 19:1-4. doi: 10.1080/10428194.2024.2404959.
    PubMed    


  50. DE SA H, Deloughery T, Kaempf A, Lachowiez C, et al
    Thromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Sep 18:1-10. doi: 10.1080/10428194.2024.2405874.
    PubMed     Abstract available


  51. OMRAN MM, Ibrahim AB, Abdelfattah R, Moussa HS, et al
    The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib.
    Leuk Lymphoma. 2024 Sep 18:1-8. doi: 10.1080/10428194.2024.2403671.
    PubMed     Abstract available


  52. CHEN EC, Flamand Y, Tiao E, DeAngelo DJ, et al
    Incidence, duration, and severity of neutropenia in adults with B-cell acute lymphoblastic leukemia receiving blinatumomab consolidation.
    Leuk Lymphoma. 2024 Sep 16:1-8. doi: 10.1080/10428194.2024.2402808.
    PubMed     Abstract available


  53. YIN Z, Gao Y, Bu X, Wang J, et al
    Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis.
    Leuk Lymphoma. 2024 Sep 5:1-13. doi: 10.1080/10428194.2024.2400228.
    PubMed     Abstract available


  54. HUNTER S, Ryland G, Pang JM, Ninkovic S, et al
    Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction.
    Leuk Lymphoma. 2024 Sep 4:1-4. doi: 10.1080/10428194.2024.2398659.
    PubMed    


  55. GIL KB, Abbott D, Amaya ML, Schwartz M, et al
    Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Sep 4:1-3. doi: 10.1080/10428194.2024.2397570.
    PubMed    


  56. DEODATO M, Frustaci AM, Zappaterra A, Rapella A, et al
    Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Sep 2:1-12. doi: 10.1080/10428194.2024.2398660.
    PubMed     Abstract available


  57. HAYASHI H, Morikawa Y, Akahoshi S, Ikegawa K, et al
    Octreotide as prophylaxis against asparaginase-associated pancreatitis: a case series study.
    Leuk Lymphoma. 2024;65:1366-1369.
    PubMed    


  58. RAVANDI F, Subklewe M, Walter RB, Vachhani P, et al
    Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
    Leuk Lymphoma. 2024;65:1281-1291.
    PubMed     Abstract available


  59. ABUASAB T, Mohamed S, Pemmaraju N, Kadia TM, et al
    BRAF mutation in myeloid neoplasm: incidences and clinical outcomes.
    Leuk Lymphoma. 2024;65:1344-1349.
    PubMed     Abstract available


  60. SABILE JMG, Swords R, Tyner JW
    Evaluating targeted therapies in older patients with TP53-mutated AML.
    Leuk Lymphoma. 2024;65:1201-1218.
    PubMed     Abstract available


  61. KOBAYASHI Y, Ando K, Imaizumi Y, Sakamoto H, et al
    RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2024 Sep 1:1-13. doi: 10.1080/10428194.2024.2393258.
    PubMed     Abstract available


    August 2024
  62. SCHWARTZ MS, Muffly LS
    Predicting relapse in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Aug 31:1-7. doi: 10.1080/10428194.2024.2387728.
    PubMed     Abstract available


  63. OSTERGAARD A, Boer JM, van Leeuwen FN, Pieters R, et al
    IKZF1 in acute lymphoblastic leukemia: the rise before the fall?
    Leuk Lymphoma. 2024 Aug 29:1-11. doi: 10.1080/10428194.2024.2396046.
    PubMed     Abstract available


  64. NGO D, Tinajero J, Song JY, Ma H, et al
    The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Aug 18:1-9. doi: 10.1080/10428194.2024.2392823.
    PubMed     Abstract available


  65. PRASERTSAN P, McNeil EB, Songthawee N, Chavananon S, et al
    Risk factors and development of a predictive score model for tumor lysis syndrome in childhood leukemia: a 10-year experience from a single tertiary hospital in Thailand.
    Leuk Lymphoma. 2024 Aug 18:1-7. doi: 10.1080/10428194.2024.2390582.
    PubMed     Abstract available


  66. JEANSELME P, Tavitian S, Lapierre L, Vergez F, et al
    Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.
    Leuk Lymphoma. 2024 Aug 14:1-6. doi: 10.1080/10428194.2024.2390572.
    PubMed     Abstract available


  67. CELLINI A, Salvalaggio A, Velasco R, Arnan M, et al
    Arsenic trioxide-induced peripheral neuropathy: prospective clinical and neurophysiological evaluation in a cohort of patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2024 Aug 13:1-4. doi: 10.1080/10428194.2024.2391899.
    PubMed    


  68. PELLAND AA, Deschenes-Simard X, Savard X, Giguere P, et al
    Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.
    Leuk Lymphoma. 2024 Aug 11:1-9. doi: 10.1080/10428194.2024.2390574.
    PubMed     Abstract available


  69. HU D, Shen K, Guo Y, Bao XB, et al
    The clinical implications of BCOR mutations in a large cohort of acute myeloid leukemia patients: a 5-year single-center retrospective study.
    Leuk Lymphoma. 2024 Aug 10:1-10. doi: 10.1080/10428194.2024.2387730.
    PubMed     Abstract available


  70. LIN L, Xue S, Chen J, Gu C, et al
    Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient.
    Leuk Lymphoma. 2024;65:1181-1185.
    PubMed    


  71. VERVOORDELDONK MYL, Hengeveld PJ, Levin MD, Langerak AW, et al
    B cell receptor signaling proteins as biomarkers for progression of CLL requiring first-line therapy.
    Leuk Lymphoma. 2024;65:1031-1043.
    PubMed     Abstract available


  72. MAEKAWA F, Hayashida M, Takeoka K, Fukutsuka K, et al
    Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively.
    Leuk Lymphoma. 2024;65:1100-1109.
    PubMed     Abstract available


  73. CHARALAMPOUS C, Doucette K, Chappell A, Vesole DH, et al
    Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression.
    Leuk Lymphoma. 2024 Aug 1:1-4. doi: 10.1080/10428194.2024.2381647.
    PubMed    


    July 2024
  74. DALAL P, Dalal J
    PTCy-ATG mutually exclusive or additive? Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 31:1-2. doi: 10.1080/10428194.2024.2379976.
    PubMed    


  75. CHOI YJ, Kook HW, Lee ST, Song J, et al
    The utility of next generation sequencing-based minimal residual disease monitoring in a post-myeloproliferative neoplasm acute myeloid leukemia patient: a case report.
    Leuk Lymphoma. 2024 Jul 29:1-4. doi: 10.1080/10428194.2024.2385498.
    PubMed    


  76. JAIN U, Rahim F, Jain B, Tresa Mathew A, et al
    Trends in location of death for individuals with acute myeloid leukemia in the United States.
    Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382330.
    PubMed    


  77. ZHANG B, Mahsoub S, Weinberg O, Germans SK, et al
    Clinicopathologic characteristics of de novo NF1-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382329.
    PubMed    


  78. SRIPORNSAWAN P, Chavananon S, Kittivisuit S, Songthawee N, et al
    Long-term survival outcome of childhood acute myeloid leukemia: a 43-year experience in Thailand, a resource-limited country.
    Leuk Lymphoma. 2024 Jul 26:1-10. doi: 10.1080/10428194.2024.2382916.
    PubMed     Abstract available


  79. TOHO M, Yasunaga M, Masuda Y, Shimura A, et al
    Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature.
    Leuk Lymphoma. 2024 Jul 25:1-5. doi: 10.1080/10428194.2024.2381646.
    PubMed    


  80. FANG J, Shankar N, Bao L, Haag M, et al
    Near-tetraploidy/tetraploidy acute myeloid leukemia with clinical, pathologic and molecular characteristics.
    Leuk Lymphoma. 2024 Jul 25:1-10. doi: 10.1080/10428194.2024.2382923.
    PubMed     Abstract available


  81. TARANTINI F, Cumbo C, Anelli L, Zagaria A, et al
    Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?
    Leuk Lymphoma. 2024 Jul 23:1-12. doi: 10.1080/10428194.2024.2381649.
    PubMed     Abstract available


  82. MORENO-LORENZANA D, Juarez-Velazquez R, Reyes-Leon A, Martinez-Anaya D, et al
    CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia.
    Leuk Lymphoma. 2024 Jul 21:1-11. doi: 10.1080/10428194.2024.2378817.
    PubMed     Abstract available


  83. TRAN QUANG V, Wagner-Ballon O, Sloma I
    Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2024 Jul 14:1-11. doi: 10.1080/10428194.2024.2378816.
    PubMed     Abstract available


  84. BORSOI L, Costa F, Milano C, Segantin G, et al
    Elicitation of societal preferences for chronic lymphocytic leukemia's treatments: a discrete choice experiment.
    Leuk Lymphoma. 2024 Jul 9:1-11. doi: 10.1080/10428194.2024.2374041.
    PubMed     Abstract available


  85. HU M, Li J, Hu T, Zhang Z, et al
    Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 7:1-10. doi: 10.1080/10428194.2024.2376179.
    PubMed     Abstract available


  86. DIEBOLD K, Bourne G, Espinoza-Gutarra M, Al-Kadhimi Z, et al
    Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jul 7:1-3. doi: 10.1080/10428194.2024.2373324.
    PubMed    


  87. TORELI ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, et al
    Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States.
    Leuk Lymphoma. 2024 Jul 5:1-10. doi: 10.1080/10428194.2024.2367057.
    PubMed     Abstract available


  88. LAVIE G, Tadmor T
    It's time to change the standard of care for hairy cell leukemia?!
    Leuk Lymphoma. 2024 Jul 5:1-3. doi: 10.1080/10428194.2024.2371497.
    PubMed    


  89. ALHAJAHJEH A, Bewersdorf JP, Bystrom RP, Zeidan AM, et al
    Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.
    Leuk Lymphoma. 2024 Jul 4:1-11. doi: 10.1080/10428194.2024.2367040.
    PubMed     Abstract available


  90. TAKIZAWA J, Teshima T, Ennishi D, Ichikawa S, et al
    Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study.
    Leuk Lymphoma. 2024 Jul 1:1-9. doi: 10.1080/10428194.2024.2370436.
    PubMed     Abstract available


  91. SURESH D, Rastogi P, Bal A, Lad D, et al
    Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profiles.
    Leuk Lymphoma. 2024 Jul 1:1-16. doi: 10.1080/10428194.2024.2372408.
    PubMed     Abstract available


  92. GOERGEN E, Al-Sawaf O
    The prognostic significance of genomic complexity in patients with CLL.
    Leuk Lymphoma. 2024;65:873-881.
    PubMed     Abstract available


    June 2024
  93. ANDERSON LJ, Girguis M, Kim E, Shewale J, et al
    A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden.
    Leuk Lymphoma. 2024 Jun 27:1-10. doi: 10.1080/10428194.2024.2360536.
    PubMed     Abstract available


  94. YU G, Zhang W, Basyal M, Nishida Y, et al
    The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.
    Leuk Lymphoma. 2024 Jun 13:1-16. doi: 10.1080/10428194.2024.2364839.
    PubMed     Abstract available


  95. ABE C, Keto J, Lilja M, Konradsen M, et al
    Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data.
    Leuk Lymphoma. 2024 Jun 11:1-9. doi: 10.1080/10428194.2024.2363430.
    PubMed     Abstract available


  96. BHATLA T, Cooper S, Hogan LE
    Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what's next?
    Leuk Lymphoma. 2024 Jun 11:1-7. doi: 10.1080/10428194.2024.2362408.
    PubMed     Abstract available


  97. CHANG JE, Wang T, Kim K, Folstad M, et al
    Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jun 10:1-9. doi: 10.1080/10428194.2024.2360535.
    PubMed     Abstract available


  98. SHORT NJ, Kantarjian H, Jabbour E
    Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
    Leuk Lymphoma. 2024 Jun 8:1-13. doi: 10.1080/10428194.2024.2364043.
    PubMed     Abstract available


  99. GERA K, Cline C, Al-Mansour Z, Medvec A, et al
    A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jun 6:1-9. doi: 10.1080/10428194.2024.2361111.
    PubMed     Abstract available


  100. SHOUSE G, Chen L, Siddiqi T, Muir A, et al
    A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Leuk Lymphoma. 2024 Jun 5:1-4. doi: 10.1080/10428194.2024.2361841.
    PubMed    


  101. FREI CR, Ryan K, Obodozie-Ofoegbu GO, Moore AM, et al
    Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2024 Jun 4:1-4. doi: 10.1080/10428194.2024.2360526.
    PubMed    


  102. FANG J, Bosma G, Aisner D, McMahon C, et al
    White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia.
    Leuk Lymphoma. 2024;65:800-807.
    PubMed     Abstract available


    May 2024
  103. MINNEMA MC, Yin X, Davi R, Keeping S, et al
    Outcomes of patients aged >/=26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
    Leuk Lymphoma. 2024 May 24:1-10. doi: 10.1080/10428194.2024.2353877.
    PubMed     Abstract available


  104. BELDZINSKA-GADEK K, Zarzycka E, Pastuszak K, Borman K, et al
    Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia.
    Leuk Lymphoma. 2024 May 22:1-11. doi: 10.1080/10428194.2024.2351194.
    PubMed     Abstract available


  105. ZHENG Y, Li J, Wen H, Weng K, et al
    Experience in improving treatment outcomes for childhood acute lymphoblastic leukemia: real-world results for a province in China, 2011-2020.
    Leuk Lymphoma. 2024 May 20:1-11. doi: 10.1080/10428194.2024.2350665.
    PubMed     Abstract available


  106. MARVIN-PEEK J, Jen WY, Kantarjian HM, McCue D, et al
    Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
    Leuk Lymphoma. 2024 May 15:1-10. doi: 10.1080/10428194.2024.2349700.
    PubMed     Abstract available


  107. DESPAS F, Chaouki M, de Barros S, Bonneau B, et al
    Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
    Leuk Lymphoma. 2024 May 15:1-3. doi: 10.1080/10428194.2024.2353330.
    PubMed    


  108. WANG CP, Ferreira JE, Placek A, Aguayo-Hiraldo P, et al
    A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2024 May 11:1-5. doi: 10.1080/10428194.2024.2347577.
    PubMed     Abstract available


  109. HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al
    Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
    Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
    PubMed     Abstract available


  110. ROGERS KA, Thompson PA
    Pairing obinutuzumab with venetoclax in relapsed CLL.
    Leuk Lymphoma. 2024;65:543-545.
    PubMed    


  111. GARCIAZ S, Berton G, Hospital MA, Guille A, et al
    Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.
    Leuk Lymphoma. 2024;65:700-703.
    PubMed    


  112. OKABE S, Moriyama M, Gotoh A
    Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.
    Leuk Lymphoma. 2024;65:696-699.
    PubMed    


  113. FATIMA N, Shen Y, Crassini K, Burling O, et al
    The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.
    Leuk Lymphoma. 2024;65:585-597.
    PubMed     Abstract available


    April 2024
  114. NESR G, Claudiani S, Milojkovic D, Innes A, et al
    Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 23:1-6. doi: 10.1080/10428194.2024.2343758.
    PubMed     Abstract available


  115. STEMPEL JM, Shallis RM, Wong R, Podoltsev NA, et al
    Challenges in management of older patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 23:1-14. doi: 10.1080/10428194.2024.2342559.
    PubMed     Abstract available


  116. BEWERSDORF JP, Patel KK, Shallis RM, Podoltsev NA, et al
    Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 22:1-9. doi: 10.1080/10428194.2024.2344052.
    PubMed     Abstract available


  117. FLECK C, Karabinos A, Cook A, Moore DC, et al
    Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Apr 22:1-2. doi: 10.1080/10428194.2024.2341999.
    PubMed    


  118. TINAJERO J, Ngo D, Zhang J, Tsai NC, et al
    High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
    Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506.
    PubMed    


  119. STEIN EM, Fathi AT, Harb WA, Colak G, et al
    Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
    Leuk Lymphoma. 2024;65:503-510.
    PubMed     Abstract available


  120. PARVIZ M, Agius R, Rotbain EC, Vainer N, et al
    Identifying CLL patients at high risk of atrial fibrillation on treatment using machine learning.
    Leuk Lymphoma. 2024;65:449-459.
    PubMed     Abstract available


  121. ALDOSS I, Clark MC, Wang X, Forman SJ, et al
    Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet?
    Leuk Lymphoma. 2024;65:440-448.
    PubMed     Abstract available


    March 2024
  122. CORTES J, Jonas BA, Schiller G, Mims A, et al
    Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
    Leuk Lymphoma. 2024 Mar 27:1-8. doi: 10.1080/10428194.2024.2333451.
    PubMed     Abstract available


  123. MATTHEWS A, Fenu E, Skuli SJ, Harris JC, et al
    Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.
    Leuk Lymphoma. 2024 Mar 27:1-4. doi: 10.1080/10428194.2024.2332505.
    PubMed    


  124. ABDALLAH AM, Hafez H, Madney Y, Ahmed S, et al
    Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Mar 21:1-4. doi: 10.1080/10428194.2024.2331625.
    PubMed    


  125. LACZKO D, Poveda-Rogers C, Matthews AH, Snaith O, et al
    RAD21 mutations in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Mar 20:1-7. doi: 10.1080/10428194.2024.2328233.
    PubMed     Abstract available


  126. ZHU J, Xu M, Ru Y, Gong H, et al
    Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2024 Mar 12:1-9. doi: 10.1080/10428194.2024.2321322.
    PubMed     Abstract available


    February 2024
  127. NASKAR S, Paul T, Kulkarni JD, Anand KC, et al
    TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the eyes - an unusual clinicopathologic presentation with hyperdiploid clone.
    Leuk Lymphoma. 2024 Feb 26:1-5. doi: 10.1080/10428194.2024.2320827.
    PubMed    


  128. HOFER KD, Buhler MM, Roncador M, Rechsteiner M, et al
    Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey.
    Leuk Lymphoma. 2024 Feb 22:1-8. doi: 10.1080/10428194.2024.2315171.
    PubMed     Abstract available


  129. MURPHY L, Siegele B, Carstens B, Hartman L, et al
    A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy.
    Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159.
    PubMed    


  130. TANG K, Lipton JH
    Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
    Leuk Lymphoma. 2024 Feb 9:1-10. doi: 10.1080/10428194.2024.2313626.
    PubMed     Abstract available


  131. YARED JA, Lee TY, Cooke CE, Johnson A, et al
    Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors.
    Leuk Lymphoma. 2024 Feb 7:1-11. doi: 10.1080/10428194.2024.2310150.
    PubMed     Abstract available


  132. EL-ASHWAH S, Salmanton-Garcia J, Bilgin YM, Itri F, et al
    The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
    Leuk Lymphoma. 2024;65:199-208.
    PubMed     Abstract available


  133. JOHNSON SM, Haberberger J, Galeotti J, Ramkissoon L, et al
    Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.
    Leuk Lymphoma. 2024;65:209-218.
    PubMed     Abstract available


    January 2024
  134. LEI MM, Sorial MN, Lou U, Yu M, et al
    Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144.
    PubMed     Abstract available


  135. NASR AA, Fund X, Barreau S, Desterke C, et al
    BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2024 Jan 31:1-4. doi: 10.1080/10428194.2024.2308665.
    PubMed    


  136. TADMOR T, Levy Yurkovski I
    Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.
    Leuk Lymphoma. 2024 Jan 22:1-4. doi: 10.1080/10428194.2024.2304026.
    PubMed    


  137. FU S, Alhaj Z, Huynh D
    Prevalence of primary chronic lymphocytic leukemia in the United States: a cross-sectional study using the SEER database.
    Leuk Lymphoma. 2024 Jan 22:1-2. doi: 10.1080/10428194.2023.2300714.
    PubMed    


  138. BANERJI V, Aw A, Laferriere N, Abdel-Samad N, et al
    Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
    Leuk Lymphoma. 2024 Jan 18:1-9. doi: 10.1080/10428194.2024.2301738.
    PubMed     Abstract available


  139. NGO D, Tinajero J, Li S, Palmer J, et al
    Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
    Leuk Lymphoma. 2024 Jan 2:1-6. doi: 10.1080/10428194.2023.2292473.
    PubMed     Abstract available


    December 2023
  140. SALTER B, Radford JM, Berg T, Leber B, et al
    The successful management of acute promyelocytic leukemia during pregnancy: a case report.
    Leuk Lymphoma. 2023 Dec 19:1-4. doi: 10.1080/10428194.2023.2295786.
    PubMed    


  141. MUTTI M, Cordella S, Parisotto A, Bettelli F, et al
    Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature.
    Leuk Lymphoma. 2023 Dec 19:1-5. doi: 10.1080/10428194.2023.2294695.
    PubMed    


  142. WANG L, Gao L, Liang Z, Cen X, et al
    Efficacy and safety of coadministration of venetoclax and anti-fungal agents under therapeutic drug monitor in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome with neutropenia: a single-center retrospective study.
    Leuk Lymphoma. 2023 Dec 9:1-10. doi: 10.1080/10428194.2023.2290465.
    PubMed     Abstract available


  143. JEN WY, Sasaki K, Rausch CR, DiNardo CD, et al
    Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
    Leuk Lymphoma. 2023 Dec 6:1-5. doi: 10.1080/10428194.2023.2290467.
    PubMed     Abstract available


  144. ZHANG F, Hu GH, Zhang LP, Xu LP, et al
    Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series study.
    Leuk Lymphoma. 2023 Dec 3:1-6. doi: 10.1080/10428194.2023.2281276.
    PubMed    


  145. MURTON A, Forsyth C, Ross DM, Grigg A, et al
    Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.
    Leuk Lymphoma. 2023;64:2018-2025.
    PubMed     Abstract available


  146. STEIN EM, de Botton S, Cluzeau T, Pigneux A, et al
    Use of tamibarotene, a potent and selective RARalpha agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
    Leuk Lymphoma. 2023;64:1992-2001.
    PubMed     Abstract available


  147. REDD RA, Ford J, Lei M, Abramson JS, et al
    Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes.
    Leuk Lymphoma. 2023;64:2296-2305.
    PubMed     Abstract available


  148. YANG T, Mahmood N, Goldberg B, Cevallos J, et al
    Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias.
    Leuk Lymphoma. 2023;64:2338-2342.
    PubMed    


  149. TOMASULO E, Paul S, Mu R, Tian X, et al
    Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
    Leuk Lymphoma. 2023;64:2306-2315.
    PubMed     Abstract available


  150. SMITH AL, Pal D, Martinez-Rico R, Eiken AP, et al
    Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
    Leuk Lymphoma. 2023;64:2333-2337.
    PubMed    


  151. ZHANG X, Wang T, Zhang Y, Wang F, et al
    Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
    Leuk Lymphoma. 2023;64:2133-2139.
    PubMed     Abstract available


    November 2023
  152. LAI X, Xiao J, Wang T, Hou C, et al
    Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission.
    Leuk Lymphoma. 2023 Nov 22:1-9. doi: 10.1080/10428194.2023.2284089.
    PubMed     Abstract available


  153. OU J, Xu X, Deng S, Liang H, et al
    Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen.
    Leuk Lymphoma. 2023 Nov 8:1-9. doi: 10.1080/10428194.2023.2278026.
    PubMed     Abstract available


  154. FATIMA N, Best OG, Belov L, Christopherson RI, et al
    The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.
    Leuk Lymphoma. 2023 Nov 7:1-8. doi: 10.1080/10428194.2023.2275530.
    PubMed     Abstract available


  155. KHOUDERCHAH CJ, Benitez LL, Marini BL, Fraga M, et al
    Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
    Leuk Lymphoma. 2023 Nov 6:1-7. doi: 10.1080/10428194.2023.2276056.
    PubMed     Abstract available


  156. SASTOW D, Tatarian J, Salib C, Lin TL, et al
    Response to 'blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives'.
    Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2274658.
    PubMed    


  157. FRATER JL
    Blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives.
    Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2273749.
    PubMed    


  158. SOSNIA O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, et al
    Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
    Leuk Lymphoma. 2023 Nov 3:1-12. doi: 10.1080/10428194.2023.2277140.
    PubMed     Abstract available


  159. TRINQUAND A, Betts DR, Harte S, Sills A, et al
    Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National cohort analysis.
    Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276061.
    PubMed    


  160. RAMACHANDRA N, Gupta M, Schwartz L, Todorova T, et al
    Role of IL8 in myeloid malignancies.
    Leuk Lymphoma. 2023;64:1742-1751.
    PubMed     Abstract available


  161. ITONAGA H, Kato T, Sawayama Y, Katsuoka S, et al
    RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL.
    Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276058.
    PubMed    


    October 2023
  162. MERIC N, Albayrak E, Gulbas Z, Kocabas F, et al
    MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis.
    Leuk Lymphoma. 2023 Oct 30:1-12. doi: 10.1080/10428194.2023.2275532.
    PubMed     Abstract available


  163. CONTRERAS YAMETTI GP, Robbins G, Chowdhury A, Narang S, et al
    SETD2 mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Oct 24:1-13. doi: 10.1080/10428194.2023.2273752.
    PubMed     Abstract available


  164. HUNTINGTON SF, de Nigris E, Puckett J, Kamal-Bahl S, et al
    Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Oct 23:1-10. doi: 10.1080/10428194.2023.2256911.
    PubMed     Abstract available


  165. LIAO C, Nie J, Xu XJ, Zhang JY, et al
    The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Oct 11:1-9. doi: 10.1080/10428194.2023.2266075.
    PubMed     Abstract available


  166. ZAHID MF, Kainthla R
    Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene.
    Leuk Lymphoma. 2023 Oct 9:1-5. doi: 10.1080/10428194.2023.2264428.
    PubMed    


  167. GAUT D, Oliai C, Boiarsky J, Zhang S, et al
    Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
    Leuk Lymphoma. 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426.
    PubMed     Abstract available


  168. YASU T, Gando Y, Shirota M, Kosugi N, et al
    Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
    Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2264427.
    PubMed    


  169. SABILE JMG, Kaempf A, Tomic K, Manu GP, et al
    A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).
    Leuk Lymphoma. 2023;64:1689-1694.
    PubMed     Abstract available


  170. CHAI J, Choudhuri J, Wang Q, Fang Y, et al
    Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
    Leuk Lymphoma. 2023;64:1662-1672.
    PubMed     Abstract available


    September 2023
  171. LI L, Zhang R, Cao W, Bian Z, et al
    Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-10. doi: 10.1080/10428194.2023.2252948.
    PubMed     Abstract available


  172. HUNTINGTON SF, Manzoor BS, Puckett JT, Kamal-Bahl S, et al
    Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-8. doi: 10.1080/10428194.2023.2255326.
    PubMed     Abstract available


  173. LESEGRETAIN A, Brunner A, Benzohra A, Fathi AT, et al
    Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.
    Leuk Lymphoma. 2023 Sep 15:1-9. doi: 10.1080/10428194.2023.2252123.
    PubMed     Abstract available


  174. IELO C, Scalzulli E, Carmosino I, Pepe S, et al
    Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice.
    Leuk Lymphoma. 2023 Sep 10:1-3. doi: 10.1080/10428194.2023.2255804.
    PubMed     Abstract available


  175. LA J, Lee MH, Brophy MT, Do NV, et al
    Baseline correlates of frailty and its association with survival in United States veterans with acute myeloid leukemia.
    Leuk Lymphoma. 2023 Sep 6:1-10. doi: 10.1080/10428194.2023.2254434.
    PubMed     Abstract available


  176. BHATNAGAR B, Zhao Q, Mims AS, Vasu S, et al
    Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
    Leuk Lymphoma. 2023 Sep 4:1-10. doi: 10.1080/10428194.2023.2253480.
    PubMed     Abstract available


  177. NEDUMANNIL R, Batterham E, Harding E, Ritchie D, et al
    Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia.
    Leuk Lymphoma. 2023 Sep 1:1-10. doi: 10.1080/10428194.2023.2251071.
    PubMed     Abstract available


    August 2023
  178. COCHRANE T, Enrico A, Gomez-Almaguer D, Hadjiev E, et al
    Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.
    Leuk Lymphoma. 2023 Aug 25:1-4. doi: 10.1080/10428194.2023.2247511.
    PubMed    


  179. SASTOW D, Tatarian J, Riazat-Kesh YJRA, Farina K, et al
    Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement.
    Leuk Lymphoma. 2023 Aug 17:1-6. doi: 10.1080/10428194.2023.2248331.
    PubMed     Abstract available


  180. DHARIWAL N, Roy Moulik N, Smriti V, Dhamne C, et al
    Clinico-radiological profile, management and follow-up of methotrexate induced neurotoxicity in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Aug 11:1-10. doi: 10.1080/10428194.2023.2245093.
    PubMed     Abstract available


  181. AGHEL N, Gustafson D, Delgado D, Atenafu EG, et al
    High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
    Leuk Lymphoma. 2023 Aug 9:1-10. doi: 10.1080/10428194.2023.2242990.
    PubMed     Abstract available


  182. SCAMUFFA MC, Latagliata R, Carmosino I, Di Veroli A, et al
    Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents.
    Leuk Lymphoma. 2023 Aug 8:1-7. doi: 10.1080/10428194.2023.2239407.
    PubMed     Abstract available


  183. BECERRIL-RICO J, Delgado-Montes YA, Ortiz-Sanchez E
    Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
    Leuk Lymphoma. 2023 Aug 7:1-10. doi: 10.1080/10428194.2023.2243357.
    PubMed     Abstract available


  184. DE MATOS RRC, Ferreira GM, Bonecker S, Rouxinol M, et al
    BCR-ABL1 co-occurring with CBFA2T3-GLIS2 and RAM immunophenotype in a non-Down syndrome infant with acute megakaryoblastic leukemia.
    Leuk Lymphoma. 2023 Aug 7:1-5. doi: 10.1080/10428194.2023.2243532.
    PubMed    


  185. ARIBI A, Salhotra A, Afkhami M, Munteanu A, et al
    WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
    Leuk Lymphoma. 2023 Aug 3:1-11. doi: 10.1080/10428194.2023.2241096.
    PubMed     Abstract available


  186. WASIFUDDIN M, Ilerhunmwuwa NP, Becerra H, Wang JC, et al
    Characteristics and survival outcomes of patients with T cell prolymphocytic leukemia in the United States: 2011-2020 analysis of the SEER database.
    Leuk Lymphoma. 2023 Aug 2:1-3. doi: 10.1080/10428194.2023.2243354.
    PubMed    


  187. LOCATELLI F, Shah B, Thomas T, Velasco K, et al
    Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review.
    Leuk Lymphoma. 2023 Aug 1:1-19. doi: 10.1080/10428194.2023.2232496.
    PubMed     Abstract available


    July 2023
  188. JEFFREY A, Presgrave P, Walsh CA, Sinn J, et al
    Successful treatment of acute lymphoblastic leukemia (ALL) during pregnancy using a pediatric-based protocol incorporating pegylated asparaginase.
    Leuk Lymphoma. 2023 Jul 30:1-4. doi: 10.1080/10428194.2023.2239406.
    PubMed    


  189. DUNN-VALADEZ S, Bathini S, Purdy KE, Bachiashvili K, et al
    Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen.
    Leuk Lymphoma. 2023 Jul 26:1-8. doi: 10.1080/10428194.2023.2234529.
    PubMed     Abstract available


  190. MUFFLY L, Young C, Feng Q, Nimke D, et al
    Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
    Leuk Lymphoma. 2023 Jul 24:1-8. doi: 10.1080/10428194.2023.2235044.
    PubMed     Abstract available


  191. BABAKHANLOU R, DiNardo C, Borthakur G
    IDH2 mutations in acute myeloid leukemia.
    Leuk Lymphoma. 2023 Jul 18:1-9. doi: 10.1080/10428194.2023.2237153.
    PubMed     Abstract available


  192. ARRIBAS I, Maluquer C, Pomares H, Carro I, et al
    B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature.
    Leuk Lymphoma. 2023 Jul 17:1-5. doi: 10.1080/10428194.2023.2234527.
    PubMed    


  193. CARDINALI D, Beldinanzi M, Ansuinelli M, Elia L, et al
    Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.
    Leuk Lymphoma. 2023 Jul 15:1-4. doi: 10.1080/10428194.2023.2235450.
    PubMed    


  194. ARGUELLO-TOMAS M, Albiol N, Jara P, Garcia-Cadenas I, et al
    Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center.
    Leuk Lymphoma. 2023 Jul 15:1-7. doi: 10.1080/10428194.2023.2232489.
    PubMed     Abstract available


  195. MARAGLINO AME, Amato V, Sammassimo S, Gigli F, et al
    Non-hepatosplenic extramedullary manifestations in patients affected by Chronic myelomonocytic leukemia. Case report and meta-analysis of the published series.
    Leuk Lymphoma. 2023 Jul 14:1-4. doi: 10.1080/10428194.2023.2234524.
    PubMed    


  196. IAQUINTA G, Scalzulli E, Angeloni S, Carmosino I, et al
    CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases.
    Leuk Lymphoma. 2023 Jul 12:1-3. doi: 10.1080/10428194.2023.2232495.
    PubMed     Abstract available


  197. CHEN H, Zhao X, Pan W, Xiao H, et al
    Integrated genomic and single-cell transcriptomic analyses reveal clonal evolution and immune signature in donor cell leukemia after haploidentical allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2023 Jul 10:1-8. doi: 10.1080/10428194.2023.2232493.
    PubMed     Abstract available


  198. ZHANG Y, Ding Y, Zhang R, Zhang L, et al
    Aberrant expression of CD5 in adult acute myeloid leukemia belonged to AML-MR, may represent a uniquely aggressive subcategory.
    Leuk Lymphoma. 2023 Jul 3:1-4. doi: 10.1080/10428194.2023.2230332.
    PubMed    


  199. GUASTAFIERRO V, Ubezio M, Manes N, Milanesi C, et al
    CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.
    Leuk Lymphoma. 2023 Jul 3:1-8. doi: 10.1080/10428194.2023.2227750.
    PubMed     Abstract available


    June 2023
  200. LUTTWAK E, Noy A, Seshan V, Saltzman LA, et al
    The efficacy of tixagevimab-cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: insights from the Leukemia and Lymphoma Society Registry.
    Leuk Lymphoma. 2023 Jun 29:1-3. doi: 10.1080/10428194.2023.2227749.
    PubMed    


  201. FEI F, Stehr H, Zehnder JL
    Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience.
    Leuk Lymphoma. 2023 Jun 17:1-9. doi: 10.1080/10428194.2023.2220450.
    PubMed     Abstract available


  202. PATEL SA
    Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3.
    Leuk Lymphoma. 2023 Jun 16:1-11. doi: 10.1080/10428194.2023.2224473.
    PubMed     Abstract available


  203. ROCCOGRANDI LM, Lovell AR, Ferrajoli A, Thompson PA, et al
    Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
    Leuk Lymphoma. 2023 Jun 15:1-8. doi: 10.1080/10428194.2023.2223740.
    PubMed     Abstract available


  204. PARISI R, Cowen EA, Gu S, Dusza S, et al
    Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab.
    Leuk Lymphoma. 2023 Jun 12:1-5. doi: 10.1080/10428194.2023.2221756.
    PubMed    


  205. CELLA D, Kelly K, de la Motte A, Toublan F, et al
    The experience of patients with acute myeloid leukemia in remission post-transplant.
    Leuk Lymphoma. 2023 Jun 8:1-10. doi: 10.1080/10428194.2023.2210711.
    PubMed     Abstract available


  206. CHEN H, Zhang Y, Jiang Y, Lin L, et al
    Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey.
    Leuk Lymphoma. 2023 Jun 6:1-7. doi: 10.1080/10428194.2023.2217711.
    PubMed     Abstract available


  207. WANG Y, Tang X, Zhu Y, Yang XX, et al
    Role of interleukins in acute myeloid leukemia.
    Leuk Lymphoma. 2023 Jun 1:1-14. doi: 10.1080/10428194.2023.2218508.
    PubMed     Abstract available


  208. MOLENDIJK EBD, van der Velden WJFM, Aarntzen EHJG, Coolen JPM, et al
    Emergence of invasive infections with Magnusiomyces species in AML patients in a single center: a possible relationship with echinocandin prophylaxis.
    Leuk Lymphoma. 2023;64:1199-1203.
    PubMed    


  209. VENUGOPAL S, Sekeres MA
    Raising the bar for lower-risk myelodysplastic syndromes.
    Leuk Lymphoma. 2023;64:1082-1091.
    PubMed     Abstract available


    May 2023
  210. BRAVO J, Baltasar Tello P, Gonzalez Garcia E, Rios Herranz E, et al
    Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
    Leuk Lymphoma. 2023 May 31:1-14. doi: 10.1080/10428194.2023.2216327.
    PubMed     Abstract available


  211. SHARMAN JP, Miranda P, Roos J, Emeribe U, et al
    Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 May 23:1-10. doi: 10.1080/10428194.2023.2212433.
    PubMed     Abstract available


  212. MURATORE E, Belotti T, Gottardi F, Sagramoso C, et al
    Miliary leukemia cutis as extramedullary relapse of KMT2A rearranged pediatric AML.
    Leuk Lymphoma. 2023 May 23:1-3. doi: 10.1080/10428194.2023.2214650.
    PubMed    


  213. TARIQ H, Shetty S
    Post PARP inhibitor therapy-related acute megakaryoblastic leukemia in a patient with germline BRCA1-mutated high-grade serous ovarian carcinoma.
    Leuk Lymphoma. 2023 May 19:1-5. doi: 10.1080/10428194.2023.2213367.
    PubMed    


  214. YIMAZ B, Koc A, Dogru O, Tufan Tas B, et al
    The results of the modified St Jude Total Therapy XV Protocol in the treatment of low- and middle-income children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 May 10:1-13. doi: 10.1080/10428194.2023.2205976.
    PubMed     Abstract available


  215. ANTONY ML, Chang D, Noble-Orcutt KE, Kay A, et al
    CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state.
    Leuk Lymphoma. 2023 May 10:1-13. doi: 10.1080/10428194.2023.2207698.
    PubMed     Abstract available


  216. LEBLANC TW
    Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies.
    Leuk Lymphoma. 2023;64:910-912.
    PubMed    


  217. RITCHIE EK, Cella D, Fabbiano F, Pigneux A, et al
    Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML.
    Leuk Lymphoma. 2023;64:938-950.
    PubMed     Abstract available


  218. RAMIA DE CAP M, Wu LP, Hirt C, Pihan GA, et al
    Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group.
    Leuk Lymphoma. 2023;64:972-980.
    PubMed     Abstract available


  219. KOPMAR NE, Gooley T, Curley N, Russell K, et al
    Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
    Leuk Lymphoma. 2023;64:1057-1059.
    PubMed    


  220. MCGHIE A, Lee J, Ferrajoli A, DiPippo AJ, et al
    Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center.
    Leuk Lymphoma. 2023;64:1050-1053.
    PubMed    


    April 2023
  221. KHELIFI RS, Huang SJ, Savage KJ, Villa D, et al
    Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada.
    Leuk Lymphoma. 2023 Apr 22:1-10. doi: 10.1080/10428194.2023.2199340.
    PubMed     Abstract available


  222. HU CC, Subramanian R, Grigg A
    Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft.
    Leuk Lymphoma. 2023 Apr 20:1-8. doi: 10.1080/10428194.2023.2203289.
    PubMed     Abstract available


  223. WALCHECK MT, Nukaya M, Ranheim EA, Matkowskyj KA, et al
    Pdx1 expression in hematopoietic cells activates Kras-mutation to drive leukemia in KC (Pdx1-Cre; LSL-Kras(G12D/+)) mice.
    Leuk Lymphoma. 2023 Apr 20:1-11. doi: 10.1080/10428194.2023.2202788.
    PubMed     Abstract available


  224. MEHYAR LS, Hartog L, Kahwash SB, Abu-Arja R, et al
    Long term survivor of MOZ-p300 therapy-related acute myeloid leukemia after matched unrelated donor bone marrow transplantation.
    Leuk Lymphoma. 2023 Apr 20:1-4. doi: 10.1080/10428194.2023.2203287.
    PubMed    


  225. LIU C, Zhang X, Mao L, Qian J, et al
    Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases.
    Leuk Lymphoma. 2023 Apr 17:1-4. doi: 10.1080/10428194.2023.2197534.
    PubMed    


  226. BRIX N, Kessel C, Foell D, Hasle H, et al
    Phagocyte-related S100 proteins and cytokines in acute lymphoblastic leukemia and their prognostic value.
    Leuk Lymphoma. 2023 Apr 17:1-9. doi: 10.1080/10428194.2023.2193855.
    PubMed     Abstract available


  227. HOFF FW, Patel PA, Belli AJ, Hansen E, et al
    Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data.
    Leuk Lymphoma. 2023 Apr 13:1-6. doi: 10.1080/10428194.2023.2197090.
    PubMed     Abstract available


  228. DECLERCK C, Giltat A, Boutemy R, Brisset-Dheilly M, et al
    Implementation of a new blood cultures sampling strategy in patients receiving intensive chemotherapy for acute leukemia and/or hematopoietic cell transplantation.
    Leuk Lymphoma. 2023 Apr 13:1-4. doi: 10.1080/10428194.2023.2196595.
    PubMed    


  229. MUSTAFA ALI MK, Williams MT, Corley EM, AlKaabba F, et al
    Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia.
    Leuk Lymphoma. 2023 Apr 12:1-10. doi: 10.1080/10428194.2023.2190432.
    PubMed     Abstract available


  230. ALLSUP D, Molica S
    Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report.
    Leuk Lymphoma. 2023 Apr 11:1-3. doi: 10.1080/10428194.2023.2199341.
    PubMed    


  231. ALDOSS I, Gu Z, Afkhami M, Mokhtari S, et al
    Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy.
    Leuk Lymphoma. 2023 Apr 6:1-10. doi: 10.1080/10428194.2023.2197538.
    PubMed     Abstract available


  232. ROBAK T, Kasprzak JD, Jesionek-Kupnicka D, Soin M, et al
    Small lymphocytic lymphoma in the heart twenty years after lymphoma diagnosis.
    Leuk Lymphoma. 2023;64:884-888.
    PubMed    


  233. YEOH ZH, Wei A
    Venetoclax and hypomethylating agent therapy for accelerated and blast phase BCR::ABL negative myeloproliferative and extramedullary disease.
    Leuk Lymphoma. 2023;64:757-760.
    PubMed    


  234. KLEINSTERN G, Slager SL
    The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review.
    Leuk Lymphoma. 2023;64:788-798.
    PubMed     Abstract available


    March 2023
  235. EYRE TA, Hess LM, Sugihara T, He D, et al
    Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study.
    Leuk Lymphoma. 2023 Mar 29:1-12. doi: 10.1080/10428194.2023.2190436.
    PubMed     Abstract available


  236. XIAO J, Xie J, Zhou B, Liu Y, et al
    RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia.
    Leuk Lymphoma. 2023 Mar 24:1-11. doi: 10.1080/10428194.2023.2190433.
    PubMed     Abstract available


  237. SALVARIS RT, Allanson B, Cheah CY
    Using next generation sequencing to guide treatment of co-existing T-cell lymphoma and chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2023 Mar 24:1-5. doi: 10.1080/10428194.2023.2192316.
    PubMed    


  238. AMMAD UD DIN M, Saeed H, Shahzad M, Liaqat H, et al
    The impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2023 Mar 20:1-5. doi: 10.1080/10428194.2023.2190435.
    PubMed    


  239. HARDELL L, Carlberg M, Nordstrom M, Eriksson M, et al
    Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma- pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia.
    Leuk Lymphoma. 2023 Mar 20:1-8. doi: 10.1080/10428194.2023.2190434.
    PubMed     Abstract available


  240. CASSADAY RD, Zarling LC, Garcia KA, Sala-Torra O, et al
    Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Mar 20:1-11. doi: 10.1080/10428194.2023.2189803.
    PubMed     Abstract available


  241. TADMOR T, Melamed G, Patalon T, Alapi H, et al
    Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir.
    Leuk Lymphoma. 2023 Mar 13:1-3. doi: 10.1080/10428194.2023.2183732.
    PubMed    


  242. PASSERINI M, Ratishvili T, Monroe JM, Temesgen Z, et al
    Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Mar 12:1-10. doi: 10.1080/10428194.2023.2183730.
    PubMed     Abstract available


  243. ROBAK T
    Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?
    Leuk Lymphoma. 2023 Mar 10:1-3. doi: 10.1080/10428194.2023.2188103.
    PubMed    


  244. ZHANG MY, Othus M, Shaw C, Schonhoff KG, et al
    Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents.
    Leuk Lymphoma. 2023 Mar 8:1-7. doi: 10.1080/10428194.2023.2186732.
    PubMed     Abstract available


  245. MAJUMDAR S, Sharma N, Sengar M, Thorat J, et al
    A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome.
    Leuk Lymphoma. 2023 Mar 8:1-11. doi: 10.1080/10428194.2023.2167491.
    PubMed     Abstract available


  246. COLTOFF A
    Leukocytosis and MPNs: Where do we stand?
    Leuk Lymphoma. 2023;64:564-572.
    PubMed     Abstract available


  247. PAUL P, Stussi G, Bruscaggin A, Rossi D, et al
    Genetics and epigenetics of CLL.
    Leuk Lymphoma. 2023;64:551-563.
    PubMed     Abstract available


  248. WANG C, Sallman DA
    Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
    Leuk Lymphoma. 2023;64:511-524.
    PubMed     Abstract available


  249. FELD J, Tremblay D, Navada SC, Silverman LR, et al
    Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Leuk Lymphoma. 2023;64:525-539.
    PubMed     Abstract available


    February 2023
  250. ARIBI A, Salhotra A, Ball B, Stein A, et al
    Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.
    Leuk Lymphoma. 2023 Feb 27:1-3. doi: 10.1080/10428194.2023.2179361.
    PubMed    


  251. MOLICA S, Giannarelli D
    Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis.
    Leuk Lymphoma. 2023 Feb 27:1-4. doi: 10.1080/10428194.2023.2181656.
    PubMed    


  252. CHOQUETTE T, Henson ES, Yang X, Johnston JB, et al
    A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER).
    Leuk Lymphoma. 2023 Feb 19:1-13. doi: 10.1080/10428194.2023.2171729.
    PubMed     Abstract available


  253. XU W, Yang S, Zhou K, Pan L, et al
    Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
    Leuk Lymphoma. 2023 Feb 17:1-5. doi: 10.1080/10428194.2022.2164692.
    PubMed    


  254. SANDLEY M, Angus J
    Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
    Leuk Lymphoma. 2023 Feb 13:1-12. doi: 10.1080/10428194.2023.2171267.
    PubMed     Abstract available


  255. OWATARI S, Tokunaga M, Nakamura D, Uozumi K, et al
    A decrease in newly diagnosed patients with adult T-cell leukemia/lymphoma in Kagoshima, a highly endemic area of HTLV-1 in southwestern Japan.
    Leuk Lymphoma. 2023 Feb 10:1-9. doi: 10.1080/10428194.2023.2173524.
    PubMed     Abstract available


  256. ARGYROPOULOS KV, Aypar U, Ewalt MD, Roshal M, et al
    Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype.
    Leuk Lymphoma. 2023 Feb 7:1-4. doi: 10.1080/10428194.2022.2161819.
    PubMed    


  257. SANBER K, Ye K, Tsai HL, Newman M, et al
    Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
    Leuk Lymphoma. 2023 Feb 6:1-10. doi: 10.1080/10428194.2023.2173523.
    PubMed     Abstract available


  258. KUTSCH N, Holmes EE, Robrecht S, Schuler G, et al
    Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.
    Leuk Lymphoma. 2023;64:478-482.
    PubMed    


    January 2023
  259. PENA C, Riva E, Schutz N, Ramirez A, et al
    Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group.
    Leuk Lymphoma. 2023 Jan 25:1-6. doi: 10.1080/10428194.2023.2171266.
    PubMed     Abstract available


  260. ZHANG S, Feng R, Bai J, Ning S, et al
    CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo.
    Leuk Lymphoma. 2023 Jan 19:1-12. doi: 10.1080/10428194.2023.2169045.
    PubMed     Abstract available


  261. BATALLER A, Haddad FG, Issa GC, Sasaki K, et al
    Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring.
    Leuk Lymphoma. 2023 Jan 19:1-4. doi: 10.1080/10428194.2023.2165395.
    PubMed    


  262. WANG J, Sun K, Chen WM, Wang X, et al
    The prognostic significance of CRLF2 expression at diagnosis in adult Ph-negative B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Jan 15:1-9. doi: 10.1080/10428194.2022.2164193.
    PubMed     Abstract available


  263. DHAKAL P, Lyden E, Joshi U, Pyakuryal A, et al
    Comorbidity burden and outcomes of older adults with acute promyelocytic leukemia: a National Cancer Database analysis of 2221 patients.
    Leuk Lymphoma. 2023 Jan 11:1-7. doi: 10.1080/10428194.2023.2165394.
    PubMed     Abstract available


  264. AQIL B, Kaur A, Ramos J, Sukhanova M, et al
    Richter transformation to aggressive plasmablastic neoplasm related to selection of a BTK-mutated clone in a patient with CLL/SLL treated by ibrutinib.
    Leuk Lymphoma. 2023;64:242-245.
    PubMed    


  265. SHAO X, Meng X, Yang H, Wang X, et al
    IFN-gamma enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway.
    Leuk Lymphoma. 2023;64:71-78.
    PubMed     Abstract available


    December 2022
  266. YASU T, Sakurai K, Hoshino M, Akazawa M, et al
    Oral azole antifungal prophylaxis in Japanese patients with chronic lymphocytic leukemia receiving ibrutinib: a nationwide cohort study.
    Leuk Lymphoma. 2022 Dec 28:1-4. doi: 10.1080/10428194.2022.2161305.
    PubMed    


  267. CHIARETTI S, Taherinasab A, Della Starza I, Canichella M, et al
    ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings.
    Leuk Lymphoma. 2022 Dec 19:1-4. doi: 10.1080/10428194.2022.2148217.
    PubMed    


  268. ASSOULINE S, Michaelis LC, Othus M, Hay AE, et al
    A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of
    Leuk Lymphoma. 2022 Dec 14:1-5. doi: 10.1080/10428194.2022.2148212.
    PubMed    


  269. BANTILAN KS, Kay NE, Parikh SA, Rabe KG, et al
    Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection.
    Leuk Lymphoma. 2022 Dec 12:1-12. doi: 10.1080/10428194.2022.2148218.
    PubMed     Abstract available


  270. BEWERSDORF JP, Patel KK, Goshua G, Shallis RM, et al
    Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia.
    Leuk Lymphoma. 2022 Dec 9:1-8. doi: 10.1080/10428194.2022.2140288.
    PubMed     Abstract available


  271. HYLAND KA, Eisel SL, Hoogland AI, Root JC, et al
    Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison.
    Leuk Lymphoma. 2022 Dec 7:1-9. doi: 10.1080/10428194.2022.2148208.
    PubMed     Abstract available


  272. WIERDA WG, Kipps TJ, Al-Sawaf O, Chyla B, et al
    Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.
    Leuk Lymphoma. 2022;63:2765-2784.
    PubMed     Abstract available


  273. HAYNES J, Jackson M, Smugar SS
    Increased risk of severe cutaneous adverse reactions when cladribine is used together with other medications with a propensity for skin reactions.
    Leuk Lymphoma. 2022;63:2965-2974.
    PubMed     Abstract available


  274. TANG C, Shen Y, Soosapilla A, Mulligan SP, et al
    Monoclonal B-cell Lymphocytosis - a review of diagnostic criteria, biology, natural history, and clinical management.
    Leuk Lymphoma. 2022;63:2795-2806.
    PubMed     Abstract available


  275. ABBAS HA, Ayoub E, Sun H, Kanagal-Shamanna R, et al
    Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment.
    Leuk Lymphoma. 2022;63:3105-3116.
    PubMed     Abstract available


  276. LONTOS K, Tsagianni A, Agha M, Raptis A, et al
    A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML.
    Leuk Lymphoma. 2022;63:3257-3260.
    PubMed    


  277. CANON A, Roy L, Chevalier X, Giraudier S, et al
    Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?
    Leuk Lymphoma. 2022;63:3175-3180.
    PubMed     Abstract available


  278. AMANAM I, Ngo D, Pullarkat V, Aldoss I, et al
    Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis.
    Leuk Lymphoma. 2022;63:3268-3270.
    PubMed    


  279. PETHUSAMY K, Seethy A, Dhar R, Karmakar A, et al
    Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.
    Leuk Lymphoma. 2022;63:3426-3432.
    PubMed     Abstract available


    November 2022
  280. MULLIGAN SP, Opat S, Cheah CY, Kuss B, et al
    Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
    Leuk Lymphoma. 2022 Nov 24:1-7. doi: 10.1080/10428194.2022.2148220.
    PubMed     Abstract available


  281. ECTOR GICG, Geelen IGP, Dinmohamed AG, Hoogendoorn M, et al
    Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands.
    Leuk Lymphoma. 2022 Nov 11:1-9. doi: 10.1080/10428194.2022.2142055.
    PubMed     Abstract available


  282. FENG X, Zheng Y, Xu J
    Morphology and clinical characteristics of a case of FIP1L1-RARA fusion-associated variant acute promyelocytic leukemia.
    Leuk Lymphoma. 2022 Nov 9:1-4. doi: 10.1080/10428194.2022.2142052.
    PubMed    


  283. CHEN WONGWORAWAT Y, Eskandari G, Gaikwad A, Marcogliese AN, et al
    Frequent detection of CBFA2T3::GLIS2 fusion and RAM-phenotype in pediatric non-Down syndrome acute megakaryoblastic leukemia: a possible novel relationship with aberrant cytoplasmic CD3 expression.
    Leuk Lymphoma. 2022 Nov 8:1-6. doi: 10.1080/10428194.2022.2140285.
    PubMed    


  284. DOUKAS PG, Cascino GJ, Meng Z, Baldridge AS, et al
    External validation of a heart failure risk score in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 Nov 4:1-9. doi: 10.1080/10428194.2022.2140289.
    PubMed     Abstract available


  285. BALL S, Loghavi S, Zeidan AM
    TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.
    Leuk Lymphoma. 2022 Nov 2:1-11. doi: 10.1080/10428194.2022.2136969.
    PubMed     Abstract available


  286. AHMED M, Pollyea DA
    Lower intensity regimens for acute myeloid leukemia: opportunities and challenges.
    Leuk Lymphoma. 2022 Nov 2:1-5. doi: 10.1080/10428194.2022.2136960.
    PubMed     Abstract available


  287. ZHANG X, Tu Y, Shen J, Feng Y, et al
    Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study.
    Leuk Lymphoma. 2022;63:2636-2644.
    PubMed     Abstract available


  288. CHANDHOK NS, Sekeres MA
    What constitutes meaningful improvement in myelodysplastic syndromes?
    Leuk Lymphoma. 2022;63:2528-2535.
    PubMed     Abstract available


  289. CHEN Y, Buhlinger K, Perissinotti AJ, Schepers AJ, et al
    Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.
    Leuk Lymphoma. 2022;63:2663-2670.
    PubMed     Abstract available


    October 2022
  290. BEWERSDORF JP, Shallis RM, Derkach A, Goldberg AD, et al
    Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
    Leuk Lymphoma. 2022 Oct 26:1-9. doi: 10.1080/10428194.2022.2136952.
    PubMed     Abstract available


  291. SHAHZAD M, Chaudhary SG, Tariq E, Mushtaq AH, et al
    Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review.
    Leuk Lymphoma. 2022 Oct 25:1-10. doi: 10.1080/10428194.2022.2136947.
    PubMed     Abstract available


  292. HELFGOTT DC, Racine-Brzostek S, Short KJ, Zhao Z, et al
    Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2022 Oct 25:1-9. doi: 10.1080/10428194.2022.2131414.
    PubMed     Abstract available


  293. GALLON R, Phelps R, Betts L, Hayes C, et al
    Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Oct 22:1-4. doi: 10.1080/10428194.2022.2131412.
    PubMed    


  294. WANG KY, Shah P, Skavla B, Fayaaz F, et al
    Vaccination efficacy in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Oct 21:1-15. doi: 10.1080/10428194.2022.2133538.
    PubMed     Abstract available


  295. OTHUS M, Thomas I, Wang X, Ariti C, et al
    Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
    Leuk Lymphoma. 2022 Oct 13:1-3. doi: 10.1080/10428194.2022.2131416.
    PubMed    


  296. OYAMA T, Matsuda K, Honda A, Yasunaga M, et al
    Long-term follow-up of central nervous system relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Leuk Lymphoma. 2022 Oct 12:1-4. doi: 10.1080/10428194.2022.2131421.
    PubMed    


  297. AQIL B, Gao J, Rahn HR, Sukhanova M, et al
    Non-leukemic presentation of acute promyelocytic leukemia as a testicular mass with associated non-canonical FLT3 mutation.
    Leuk Lymphoma. 2022 Oct 10:1-4. doi: 10.1080/10428194.2022.2131425.
    PubMed    


  298. PAULUS A, Malavasi F, Chanan-Khan A
    CD38 as a multifaceted immunotherapeutic target in CLL.
    Leuk Lymphoma. 2022;63:2265-2275.
    PubMed     Abstract available


  299. USTUN C, Warlick E, Nathan S, Burns LJ, et al
    Transplantation provides superior survival high risk myeloid malignancies in older patients.
    Leuk Lymphoma. 2022;63:2494-2498.
    PubMed    


  300. ENGVALL M, Karlsson Y, Kuchinskaya E, Jornegren A, et al
    Familial platelet disorder due to germline exonic deletions in RUNX1: a diagnostic challenge with distinct alterations of the transcript isoform equilibrium.
    Leuk Lymphoma. 2022;63:2311-2320.
    PubMed     Abstract available


    September 2022
  301. ISHITSUKA K, Yoshizawa Y, Nishikii H, Kusakabe M, et al
    Novel translocation of POGZ/STK11 in de novo mast cell leukemia with KIT D816H mutation.
    Leuk Lymphoma. 2022 Sep 20:1-5. doi: 10.1080/10428194.2022.2123235.
    PubMed    


  302. SIMON F, Giza A, Robrecht S, Fink AM, et al
    Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older.
    Leuk Lymphoma. 2022 Sep 18:1-8. doi: 10.1080/10428194.2022.2123223.
    PubMed     Abstract available


  303. SHAHZAD M, Tariq E, Chaudhary SG, Anwar I, et al
    Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2022 Sep 15:1-9. doi: 10.1080/10428194.2022.2123228.
    PubMed     Abstract available


  304. LIU X, Zou Y, Zhang L, Zhang Y, et al
    Characteristics and prognosis of children with recurrent T-cell acute lymphoblastic leukemia: a long-term follow-up report in China.
    Leuk Lymphoma. 2022 Sep 15:1-13. doi: 10.1080/10428194.2022.2123224.
    PubMed     Abstract available


  305. ZAINALDIN C, Arora S, Bathini S, Gupta U, et al
    Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents.
    Leuk Lymphoma. 2022 Sep 15:1-4. doi: 10.1080/10428194.2022.2113530.
    PubMed    


  306. BEHDAD A, Schipma MJ, Ma S, Chen YH, et al
    Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10.
    Leuk Lymphoma. 2022 Sep 14:1-5. doi: 10.1080/10428194.2022.2123236.
    PubMed    


  307. MUKAE J, Sadato D, Toya T, Watanabe S, et al
    Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Sep 14:1-4. doi: 10.1080/10428194.2022.2116936.
    PubMed    


  308. EDAHIRO T, Ureshino H, Chishaki R, Fujino K, et al
    Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis.
    Leuk Lymphoma. 2022 Sep 13:1-2. doi: 10.1080/10428194.2022.2123230.
    PubMed    


  309. CAI Z, Liu Y, Tang B, Wu Z, et al
    Dynamics of minimal residual disease defines a novel risk-classification and the role of allo-HSCT in adult Ph-negative B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Sep 13:1-10. doi: 10.1080/10428194.2022.2115841.
    PubMed     Abstract available


  310. BALL BJ, Arslan S, Koller P, Ngo D, et al
    Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).
    Leuk Lymphoma. 2022 Sep 10:1-5. doi: 10.1080/10428194.2022.2116934.
    PubMed    


  311. PATIL P, Toprak UH, Seufert J, Braun T, et al
    Exploration of whole genome and transcriptome sequencing data lacks evidence for oncogenic viral elements to drive the pathogenesis of T-cell prolymphocytic leukemia.
    Leuk Lymphoma. 2022 Sep 9:1-4. doi: 10.1080/10428194.2022.2116933.
    PubMed    


  312. ANDRITSOS LA, Anghelina M, Neal J, Blachly JS, et al
    Development of a distributed international patient data registry for hairy cell leukemia.
    Leuk Lymphoma. 2022 Sep 7:1-11. doi: 10.1080/10428194.2022.2109157.
    PubMed     Abstract available


  313. NAGATA A, Otsuka Y, Konuma R, Adachi H, et al
    Weight-adjusted urinary creatinine excretion predicts transplant outcomes in adult patients with acute myeloid leukemia in complete remission.
    Leuk Lymphoma. 2022 Sep 6:1-11. doi: 10.1080/10428194.2022.2109334.
    PubMed     Abstract available


  314. TIBOUT P, Ledjiar O, Athale U, Rayar M, et al
    Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C.
    Leuk Lymphoma. 2022 Sep 6:1-9. doi: 10.1080/10428194.2022.2118536.
    PubMed     Abstract available


  315. LU Y, Sun RJ, Zhang JP, Xu F, et al
    Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.
    Leuk Lymphoma. 2022 Sep 6:1-8. doi: 10.1080/10428194.2022.2118531.
    PubMed     Abstract available


  316. WEI Y, Zheng H, Lockyer PP, Darbaniyan F, et al
    MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2022 Sep 5:1-11. doi: 10.1080/10428194.2022.2116932.
    PubMed     Abstract available


  317. DURINIKOVA A, Folta A, Pardy F, Svaton J, et al
    Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients.
    Leuk Lymphoma. 2022 Sep 1:1-4. doi: 10.1080/10428194.2022.2116931.
    PubMed    


  318. GAGNON MF, Smadbeck JB, Sharma N, Blackburn PR, et al
    Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL.
    Leuk Lymphoma. 2022;63:2243-2246.
    PubMed    


  319. MCCAY J, Gribben JG
    The role of BTK inhibitors on the tumor microenvironment in CLL.
    Leuk Lymphoma. 2022;63:2023-2032.
    PubMed     Abstract available


    August 2022
  320. COSTA DFD, Filiu-Braga LDC, Silva-Carvalho AE, Schiavinato JL, et al
    Transcriptional deregulation of LSD1 and LSD2 is associated with cytogenetic risk in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Aug 25:1-5. doi: 10.1080/10428194.2022.2116935.
    PubMed    


  321. LALAYANNI C, Demosthenous C, Iskas M, Kelaidi C, et al
    Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes.
    Leuk Lymphoma. 2022 Aug 24:1-10. doi: 10.1080/10428194.2022.2113527.
    PubMed     Abstract available


  322. NAMJOSHI NS, Keegan THM, Li QC, Chung JH, et al
    Treatment-related toxicities associated with hospitalization in children, adolescents, and young adults with acute lymphoblastic leukemia: population level analysis.
    Leuk Lymphoma. 2022 Aug 23:1-9. doi: 10.1080/10428194.2022.2113533.
    PubMed     Abstract available


  323. ZAK T, Gao J, Behdad A, Mehta J, et al
    Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients.
    Leuk Lymphoma. 2022 Aug 22:1-8. doi: 10.1080/10428194.2022.2113524.
    PubMed     Abstract available


  324. SUDUTAN T, Erbilgin Y, Hatirnaz Ng O, Karaman S, et al
    Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Aug 3:1-9. doi: 10.1080/10428194.2022.2095630.
    PubMed     Abstract available


  325. PERAGINE N, De Propris MS, Intoppa S, Milani ML, et al
    Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response.
    Leuk Lymphoma. 2022 Aug 1:1-5. doi: 10.1080/10428194.2022.2105324.
    PubMed    


  326. TESTI AM, Al-Jadiry MF, Ghali HH, Fadhil SA, et al
    Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation.
    Leuk Lymphoma. 2022 Aug 1:1-8. doi: 10.1080/10428194.2022.2105328.
    PubMed     Abstract available


  327. SRINIVASAN S
    Optimal dosing of cytarabine in childhood acute myeloid leukemia: do we have the answer yet?
    Leuk Lymphoma. 2022 Aug 1:1-3. doi: 10.1080/10428194.2022.2105327.
    PubMed    


  328. BASSIG BA, Hu W, Morton LM, Ji BT, et al
    Incidence of myeloid malignancies by subtype in Hong Kong and comparisons with Asian and white men and women in the United States.
    Leuk Lymphoma. 2022;63:1917-1924.
    PubMed     Abstract available


  329. MACARON W, Sargsyan Z, Short NJ
    Hyperleukocytosis and leukostasis in acute and chronic leukemias.
    Leuk Lymphoma. 2022;63:1780-1791.
    PubMed     Abstract available


  330. CHEN EC, Liu Y, Harris CE, Winer ES, et al
    Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
    Leuk Lymphoma. 2022;63:1934-1941.
    PubMed     Abstract available


  331. COZAD M, Stump SE, Buhlinger K, Collins J 4th, et al
    Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
    Leuk Lymphoma. 2022;63:1831-1838.
    PubMed     Abstract available


    July 2022
  332. DHARIA P, Swartz MD, Bernhardt MB, Chen H, et al
    Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Jul 27:1-7. doi: 10.1080/10428194.2022.2102621.
    PubMed     Abstract available


  333. KUSS B, Nagarajan C, Hsieh WS, Cheah CY, et al
    Practical management of chronic lymphocytic leukemia with acalabrutinib.
    Leuk Lymphoma. 2022 Jul 19:1-10. doi: 10.1080/10428194.2022.2098289.
    PubMed     Abstract available


  334. DAVER N, Jonas BA, Medeiros BC, Patil U, et al
    Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2022 Jul 14:1-4. doi: 10.1080/10428194.2022.2092853.
    PubMed    


  335. YAN W, Fan H, Xu J, Liu J, et al
    The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
    Leuk Lymphoma. 2022 Jul 12:1-10. doi: 10.1080/10428194.2022.2098290.
    PubMed     Abstract available


  336. KLINGLER F, Alsdorf WH, Ghandili S, Wolschke C, et al
    Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
    Leuk Lymphoma. 2022 Jul 5:1-7. doi: 10.1080/10428194.2022.2092855.
    PubMed     Abstract available


    June 2022
  337. XU Z, Yin J, Sun Q, Hu J, et al
    The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
    Leuk Lymphoma. 2022 Jun 25:1-11. doi: 10.1080/10428194.2022.2090549.
    PubMed     Abstract available


  338. XU GF, Liu LM, Wang M, Zhang ZB, et al
    Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China.
    Leuk Lymphoma. 2022 Jun 24:1-11. doi: 10.1080/10428194.2022.2090550.
    PubMed     Abstract available


  339. RAA DGT, van der Straten L, van Gelder M, Kersting S, et al
    Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
    Leuk Lymphoma. 2022 Jun 23:1-14. doi: 10.1080/10428194.2022.2084731.
    PubMed     Abstract available


  340. DHAKAL P, Joshi U, Lyden E, Pyakuryal A, et al
    Association of insurance types and outcomes in acute promyelocytic leukemia.
    Leuk Lymphoma. 2022 Jun 23:1-9. doi: 10.1080/10428194.2022.2090554.
    PubMed     Abstract available


  341. ZONG L, Xie J, Kong J, Bao X, et al
    Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Jun 23:1-3. doi: 10.1080/10428194.2022.2064984.
    PubMed    


  342. SERPENTI F, Sciume M, Galassi G, Saporiti G, et al
    Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse.
    Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.
    PubMed    


  343. NGO D, Otoukesh S, Stein AS, Forman S, et al
    The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Jun 21:1-3. doi: 10.1080/10428194.2022.2090555.
    PubMed    


  344. TEDJASEPUTRA A, Kuzich JA, Thiagarajah N, Teh TC, et al
    Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic.
    Leuk Lymphoma. 2022 Jun 21:1-4. doi: 10.1080/10428194.2022.2087065.
    PubMed    


  345. KOHN M, Alsuliman T, Lamure S, Cheminant M, et al
    Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia patients during the Omicron outbreak.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086249.
    PubMed    


  346. SYMES E, Wang P, Lager AM, Bishop MR, et al
    TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.
    Leuk Lymphoma. 2022 Jun 18:1-4. doi: 10.1080/10428194.2022.2087070.
    PubMed    


  347. MOLICA S, Allsup DJ, Polliack A
    Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jun 15:1-3. doi: 10.1080/10428194.2022.2087072.
    PubMed    


  348. YU G, Lu W, Chen X, Li Y, et al
    Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission.
    Leuk Lymphoma. 2022 Jun 11:1-12. doi: 10.1080/10428194.2022.2086243.
    PubMed     Abstract available


  349. LYU X, Li T, Zhu D, Cheng Y, et al
    Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2022 Jun 11:1-10. doi: 10.1080/10428194.2022.2080821.
    PubMed     Abstract available


  350. SABURI M, Sakata M, Takata H, Miyazaki Y, et al
    Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience.
    Leuk Lymphoma. 2022 Jun 10:1-5. doi: 10.1080/10428194.2022.2086250.
    PubMed    


  351. XU J, Hao Z, Chen X, Hong M, et al
    The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
    Leuk Lymphoma. 2022 Jun 2:1-9. doi: 10.1080/10428194.2022.2081323.
    PubMed     Abstract available


  352. GADAUD N, Leroy H, Berard E, Tavitian S, et al
    Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study.
    Leuk Lymphoma. 2022;63:1398-1406.
    PubMed     Abstract available


  353. MATUTES E, Polliack A
    Is ibrutinib the gold standard for therapy - naive elderly patients with CLL?
    Leuk Lymphoma. 2022;63:1265-1266.
    PubMed    


  354. TAHIR F, Sy J, Reddel S, Trotman J, et al
    Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Leuk Lymphoma. 2022;63:1464-1468.
    PubMed     Abstract available


  355. SHARPLIN KM, Marks DI
    The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL).
    Leuk Lymphoma. 2022;63:1292-1301.
    PubMed     Abstract available


  356. BALL S, Komrokji RS, Sallman DA
    Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.
    Leuk Lymphoma. 2022;63:1281-1291.
    PubMed     Abstract available


    May 2022
  357. MAENG CV, Christiansen CF, Liu KD, Kamper P, et al
    Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.
    Leuk Lymphoma. 2022 May 18:1-11. doi: 10.1080/10428194.2022.2074984.
    PubMed     Abstract available


  358. MACHHERNDL-SPANDL S, Vockenhuber T, Binder M, Weltermann A, et al
    Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 May 13:1-6. doi: 10.1080/10428194.2022.2068006.
    PubMed     Abstract available


  359. LI Z, Peng L, Li Y, Zhang J, et al
    Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia.
    Leuk Lymphoma. 2022 May 11:1-12. doi: 10.1080/10428194.2022.2070912.
    PubMed     Abstract available


  360. ASOUBAR S, Esfahani A, Vahedi A, Mohammadi SM, et al
    Responsible enzymes for metabolizing vitamin D in patients with acute leukemia and the relationship with treatment outcomes: a case-control study.
    Leuk Lymphoma. 2022 May 4:1-7. doi: 10.1080/10428194.2022.2056174.
    PubMed     Abstract available


  361. EVANS MG, Shestakova A, Haghighi N, Zhao X, et al
    Rare case of leptomeningeal small lymphocytic lymphoma with TP53 mutation detected by deep next-generation sequencing.
    Leuk Lymphoma. 2022 May 3:1-5. doi: 10.1080/10428194.2022.2070911.
    PubMed     Abstract available


  362. SZCZEPANEK E, Chukwu O, Kaminska M, Wysoglad H, et al
    Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience.
    Leuk Lymphoma. 2022 May 2:1-11. doi: 10.1080/10428194.2022.2068000.
    PubMed     Abstract available


  363. PREBET T, Goldberg AD, Jurcic JG, Khaled S, et al
    A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.
    Leuk Lymphoma. 2022 May 1:1-9. doi: 10.1080/10428194.2022.2057484.
    PubMed     Abstract available


  364. QIN T, Cheng Y, Wang X
    RNA-binding proteins as drivers of AML and novel therapeutic targets.
    Leuk Lymphoma. 2022;63:1045-1057.
    PubMed     Abstract available


  365. SAUMELL S, Fernandez-Serrano M, Mesa A, Lopez-Cadenas F, et al
    Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes.
    Leuk Lymphoma. 2022;63:1227-1235.
    PubMed     Abstract available


  366. LI J, Liao D, Wang F, Wang Z, et al
    RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both in vitro and in vivo.
    Leuk Lymphoma. 2022;63:1167-1179.
    PubMed     Abstract available


    April 2022
  367. QI D, Wang J, Zhao Y, Yang Y, et al
    JMJD1C-regulated lipid synthesis contributes to the maintenance of MLL-rearranged acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 25:1-12. doi: 10.1080/10428194.2022.2068004.
    PubMed     Abstract available


  368. LI Q, Liang C, Xu X, Zhang C, et al
    CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 23:1-13. doi: 10.1080/10428194.2022.2064986.
    PubMed     Abstract available


  369. PHAM TM, Quy PN, Amin K, Walker E, et al
    Average lifespan shortened due to Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia in Japan, 1990-2015.
    Leuk Lymphoma. 2022 Apr 23:1-10. doi: 10.1080/10428194.2022.2064990.
    PubMed     Abstract available


  370. PETROV D, Timilshina N, Papadopoulos E, Alibhai SMH, et al
    Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive chemotherapy.
    Leuk Lymphoma. 2022 Apr 22:1-8. doi: 10.1080/10428194.2022.2064993.
    PubMed     Abstract available


  371. MEMOLI M, Genthon A, Favale F, Lapusan S, et al
    Prognostic impact of early minimal residual disease combined with complete molecular evaluation in acute myeloid leukemia with mutated NPM1: a single center study.
    Leuk Lymphoma. 2022 Apr 22:1-9. doi: 10.1080/10428194.2022.2064987.
    PubMed     Abstract available


  372. SHORT NJ, Borthakur G, Pemmaraju N, Dinardo CD, et al
    A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 20:1-10. doi: 10.1080/10428194.2022.2062345.
    PubMed     Abstract available


  373. NAKASE K, Tanaka I, Tawara I, Shiku H, et al
    CD22 expression in acute myeloid leukemia: close correlation with interleukin-2 receptor alpha-chain (CD25) expression and poor prognosis.
    Leuk Lymphoma. 2022 Apr 20:1-3. doi: 10.1080/10428194.2022.2062346.
    PubMed    


  374. XUE S, Huang W, Liu F, Zhang Y, et al
    Rapid response to avapritinib of acute myeloid leukemia with t(8;21) and KIT mutation relapse post allo-HSCT.
    Leuk Lymphoma. 2022 Apr 19:1-4. doi: 10.1080/10428194.2022.2064994.
    PubMed    


  375. MIRANTI E, Ho DY, Enriquez K, Subramanian AK, et al
    Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 12:1-7. doi: 10.1080/10428194.2022.2060504.
    PubMed     Abstract available


  376. MANGAONKAR AA, Patnaik MM
    Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation.
    Leuk Lymphoma. 2022 Apr 4:1-9. doi: 10.1080/10428194.2022.2056175.
    PubMed     Abstract available


  377. MINDIOLA ROMERO AE, Johnston MA, Giffin JT, Khan WA, et al
    SNP-based chromosomal microarray characterization in a series of pure erythroid leukemia.
    Leuk Lymphoma. 2022 Apr 3:1-4. doi: 10.1080/10428194.2022.2057489.
    PubMed    


  378. FERNANDEZ A, Perez-Martinez A, Escudero A, Mirones I, et al
    Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits.
    Leuk Lymphoma. 2022 Apr 3:1-5. doi: 10.1080/10428194.2022.2057490.
    PubMed    


  379. HADDAD F, Kantarjian H, Issa GC, Jabbour E, et al
    Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.
    Leuk Lymphoma. 2022 Apr 1:1-4. doi: 10.1080/10428194.2022.2045599.
    PubMed    


  380. MIYAMOTO T, Sanford D, Tomuleasa C, Hsiao HH, et al
    Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy().
    Leuk Lymphoma. 2022;63:928-938.
    PubMed     Abstract available


    March 2022
  381. KIERDORF F, Zimmer P, Joisten N, Kiesl D, et al
    L-kynurenine as a prognostic marker for early mortality in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2022 Mar 31:1-4. doi: 10.1080/10428194.2022.2053534.
    PubMed    


  382. OCHS MA, Marini BL, Benitez LL, Stump SE, et al
    Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Mar 28:1-10. doi: 10.1080/10428194.2022.2053530.
    PubMed     Abstract available


  383. PERKINS B, Showel M, Schoch L, Imus PH, et al
    CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-7. doi: 10.1080/10428194.2022.2038375.
    PubMed     Abstract available


  384. DEODATO M, Frustaci AM, Sportoletti P, Laurenti L, et al
    How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-4. doi: 10.1080/10428194.2022.2053532.
    PubMed    


  385. LIPTON NJ, Lipton JH
    Making the case for the case report - informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients.
    Leuk Lymphoma. 2022 Mar 25:1-2. doi: 10.1080/10428194.2022.2056180.
    PubMed    


  386. GHOSH S, Roth J, Babushok D, Lim M, et al
    Significance of RUNX1 mutation in BCR-ABL1 positive acute myeloid leukemia - a diagnostic dilemma in a young woman with persistent bleeding.
    Leuk Lymphoma. 2022 Mar 15:1-5. doi: 10.1080/10428194.2022.2047673.
    PubMed    


  387. GRAVENO ME, Carulli A, Freyer CW, Mangan BL, et al
    Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
    Leuk Lymphoma. 2022 Mar 8:1-6. doi: 10.1080/10428194.2022.2042688.
    PubMed     Abstract available


  388. TETTAMANTI S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, et al
    Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 8:1-14. doi: 10.1080/10428194.2022.2043299.
    PubMed     Abstract available


  389. XIE W, Raess PW, Dunlap J, Hoyos CM, et al
    Adult acute myeloid leukemia patients with NUP98 rearrangement have frequent cryptic translocations and unfavorable outcome.
    Leuk Lymphoma. 2022 Mar 8:1-10. doi: 10.1080/10428194.2022.2047672.
    PubMed     Abstract available


  390. COLLARD JP, McKenna MK, Noothi SK, Alhakeem SS, et al
    Role of the splenic microenvironment in chronic lymphocytic leukemia development in Emicro-TCL1 transgenic mice.
    Leuk Lymphoma. 2022 Mar 8:1-13. doi: 10.1080/10428194.2022.2045596.
    PubMed     Abstract available


  391. ESHIBONA N, Giwa A, Rossouw SC, Gamieldien J, et al
    Upregulation of FHL1, SPNS3, and MPZL2 predicts poor prognosis in pediatric acute myeloid leukemia patients with FLT3-ITD mutation.
    Leuk Lymphoma. 2022 Mar 6:1-10. doi: 10.1080/10428194.2022.2045594.
    PubMed     Abstract available


  392. COLLINS J 4TH, Stump SE, Heiling H, Muir M, et al
    Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 6:1-8. doi: 10.1080/10428194.2022.2045597.
    PubMed     Abstract available


  393. GUPTA DG, Varma N, Kumar A, Naseem S, et al
    PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1-like acute lymphoblastic leukaemia in Indian patients.
    Leuk Lymphoma. 2022;63:633-643.
    PubMed     Abstract available


  394. BENDIG S, Stengel A, Walter W, Meggendorfer M, et al
    Diagnostic challenge of identifying cases with recurrent t(8;14)(q24.21;q32.2) Involving BCL11B in acute leukemias of ambiguous lineage: an analysis of eight patients.
    Leuk Lymphoma. 2022;63:747-750.
    PubMed    


    February 2022
  395. FU W, Huang A, Xu L, Peng Y, et al
    Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2022 Feb 28:1-8. doi: 10.1080/10428194.2022.2045600.
    PubMed     Abstract available


  396. SIDDIQI T, Coutre S, McKinney M, Barr PM, et al
    Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Leuk Lymphoma. 2022 Feb 28:1-9. doi: 10.1080/10428194.2022.2038372.
    PubMed     Abstract available


  397. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    PubMed     Abstract available


  398. MEHTA-SHAH N, Bartlett NL, Kahl B, Watkins MP, et al
    COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.
    Leuk Lymphoma. 2022 Feb 27:1-5. doi: 10.1080/10428194.2022.2038377.
    PubMed    


  399. VALDEZ BC, Yuan B, Murray D, Nieto Y, et al
    Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells.
    Leuk Lymphoma. 2022 Feb 20:1-11. doi: 10.1080/10428194.2022.2042689.
    PubMed     Abstract available


  400. KAUMEYER B, Fidai S, Sukhanova M, Yap KL, et al
    MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Feb 16:1-9. doi: 10.1080/10428194.2022.2025797.
    PubMed     Abstract available


  401. NAGAYAMA T, Fujiwara SI, Kikuchi T, Onda K, et al
    Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation.
    Leuk Lymphoma. 2022 Feb 14:1-7. doi: 10.1080/10428194.2022.2034159.
    PubMed     Abstract available


  402. KOCHNEVA CAPITAL O, CYRILLICL, Kislova M, Zhelnova EI, Petrenko AA, et al
    COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
    Leuk Lymphoma. 2022 Feb 13:1-10. doi: 10.1080/10428194.2022.2034157.
    PubMed     Abstract available


  403. AKHTAR OS, Groman A, Singh A, Ghione P, et al
    Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study.
    Leuk Lymphoma. 2022 Feb 13:1-10. doi: 10.1080/10428194.2021.2012662.
    PubMed     Abstract available


  404. FAZIO F, Cunsolo G, Mancini F, De Propris MS, et al
    Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia.
    Leuk Lymphoma. 2022 Feb 8:1-3. doi: 10.1080/10428194.2022.2032035.
    PubMed    


  405. YUAN Y, Li J, Xue TL, Hu HR, et al
    Prognostic significance of NOTCH1/FBXW7 mutations in pediatric T cell acute lymphoblastic leukemia: a study of minimal residual disease risk-directed CCLG-ALL 2008 treatment protocol.
    Leuk Lymphoma. 2022 Feb 6:1-10. doi: 10.1080/10428194.2022.2032033.
    PubMed     Abstract available


  406. SHALLIS RM, Gore SD
    Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis.
    Leuk Lymphoma. 2022 Feb 2:1-10. doi: 10.1080/10428194.2022.2034156.
    PubMed     Abstract available


  407. RAMALINGAM TR, Mohanraj S, Muthu A, Prabhakar V, et al
    Independent diagnostic utility of CD20, CD200, CD43 and CD45 in chronic lymphocytic leukaemia.
    Leuk Lymphoma. 2022;63:377-384.
    PubMed     Abstract available


    January 2022
  408. ROY T, An JB, Doucette K, Chappell AM, et al
    Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.
    Leuk Lymphoma. 2022 Jan 25:1-3. doi: 10.1080/10428194.2021.2010065.
    PubMed    


  409. AMREIN P, Ballen K, Stevenson K, Brunner A, et al
    Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
    Leuk Lymphoma. 2022 Jan 25:1-8. doi: 10.1080/10428194.2021.2018582.
    PubMed     Abstract available


  410. CHAUDHARY S, Ganguly S, Singh A, Palanichamy JK, et al
    Mitochondrial biogenesis gene POLG correlates with outcome in pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2022 Jan 25:1-4. doi: 10.1080/10428194.2021.2010063.
    PubMed    


  411. WANG SSY
    Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application.
    Leuk Lymphoma. 2022 Jan 22:1-10. doi: 10.1080/10428194.2022.2027401.
    PubMed     Abstract available


  412. MELEN CM, Merrien M, Wasik AM, Panagiotidis G, et al
    Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jan 17:1-11. doi: 10.1080/10428194.2021.2020776.
    PubMed     Abstract available


  413. BURGER JA, Robak T, Demirkan F, Bairey O, et al
    Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
    Leuk Lymphoma. 2022 Jan 11:1-12. doi: 10.1080/10428194.2021.2020779.
    PubMed     Abstract available


  414. SASAKI K, Kantarjian H, Jabbour E
    Prediction for sustained deep molecular response for treatment-free remission.
    Leuk Lymphoma. 2022;63:5-6.
    PubMed    


  415. WILSON NR, Bover L, Konopleva M, Han L, et al
    CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies.
    Leuk Lymphoma. 2022;63:19-30.
    PubMed     Abstract available


  416. HALPERN AB, Othus M, Howard NP, Hendrie PC, et al
    Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy.
    Leuk Lymphoma. 2022;63:142-151.
    PubMed     Abstract available


  417. EL HUSSEIN S, Hu S, Fang H, Garces S, et al
    Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity.
    Leuk Lymphoma. 2022;63:235-238.
    PubMed    


    December 2021
  418. MESSORI A, Rivano M, Mengato D, Cancanelli L, et al
    A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Dec 31:1-4. doi: 10.1080/10428194.2021.2022141.
    PubMed    


  419. ROBOZ GJ, Yee K, Verma A, Borthakur G, et al
    Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Leuk Lymphoma. 2021 Dec 19:1-5. doi: 10.1080/10428194.2021.2012667.
    PubMed    


  420. MCQUILTEN ZK, Busija L, Seymour JF, Stanworth S, et al
    Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
    Leuk Lymphoma. 2021 Dec 17:1-8. doi: 10.1080/10428194.2021.2012664.
    PubMed     Abstract available


  421. HUNTINGTON SF, Ingham MP, Okonkwo L, Singh A, et al
    Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020.
    Leuk Lymphoma. 2021 Dec 16:1-11. doi: 10.1080/10428194.2021.2012666.
    PubMed     Abstract available


  422. KANAGAL-SHAMANNA R, Bao H, Kearney H, Smoley S, et al
    Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia.
    Leuk Lymphoma. 2021 Dec 13:1-11. doi: 10.1080/10428194.2021.2010061.
    PubMed     Abstract available


  423. CABRERA ME, Marinov N, Roa M, Castillo JJ, et al
    Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile.
    Leuk Lymphoma. 2021 Dec 10:1-7. doi: 10.1080/10428194.2021.2012663.
    PubMed     Abstract available


  424. SALHOTRA A, Yang D, Mokhtari S, Hui S, et al
    Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2021 Dec 9:1-7. doi: 10.1080/10428194.2021.2012661.
    PubMed     Abstract available


  425. SHEN X, Zhang L, Xing S, Zhang XW, et al
    Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cells.
    Leuk Lymphoma. 2021 Dec 8:1-9. doi: 10.1080/10428194.2021.2008382.
    PubMed     Abstract available


  426. EGELI DB, Hanfstein B, Lauseker M, Pfirrmann M, et al
    SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment.
    Leuk Lymphoma. 2021 Dec 6:1-8. doi: 10.1080/10428194.2021.2010059.
    PubMed     Abstract available


  427. BANASZAK LG, Reinig E, Lasarev MR, Mattison RJ, et al
    Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes.
    Leuk Lymphoma. 2021 Dec 6:1-10. doi: 10.1080/10428194.2021.1999435.
    PubMed     Abstract available


  428. GAGEZ AL, Paul F, Alaterre E, Gouilleux-Gruart V, et al
    Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study.
    Leuk Lymphoma. 2021;62:3160-3169.
    PubMed     Abstract available


  429. BEWERSDORF JP, Stone RM, Tallman MS, Stahl M, et al
    Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?
    Leuk Lymphoma. 2021;62:3318-3319.
    PubMed    


  430. BEWERSDORF JP, Derkach A, Gowda L, Menghrajani K, et al
    Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
    Leuk Lymphoma. 2021;62:3394-3401.
    PubMed     Abstract available


  431. SMALL SH, Altman JK, Platanias LC
    Interferon maintenance for prevention of relapse in favorable risk AML?
    Leuk Lymphoma. 2021;62:2818-2819.
    PubMed    


  432. STABER PB, Jurczak W, Greil R, Vucinic V, et al
    Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
    Leuk Lymphoma. 2021;62:3440-3451.
    PubMed     Abstract available


  433. LUKES J, Wolthers BO, Altaf Raja R, Uhrinova K, et al
    Pancreatitis-associated protein as an early marker of asparaginase-associated pancreatitis.
    Leuk Lymphoma. 2021;62:3506-3510.
    PubMed    


  434. LU H, Li ZY, Ding M, Liang C, et al
    Trametinib enhances ATRA-induced differentiation in AML cells.
    Leuk Lymphoma. 2021;62:3361-3372.
    PubMed     Abstract available


  435. LOO S, Wei AH
    Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?
    Leuk Lymphoma. 2021;62:3073-3077.
    PubMed    


  436. WAGNER-JOHNSTON ND, Sharman J, Furman RR, Salles G, et al
    Idelalisib immune-related toxicity is associated with improved treatment response.
    Leuk Lymphoma. 2021;62:2915-2920.
    PubMed     Abstract available


  437. MEGHEREA O, Janes C, Kowalski A, Baron J, et al
    Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome.
    Leuk Lymphoma. 2021;62:3219-3225.
    PubMed     Abstract available


  438. SHIMONY S, Bar-Sever E, Berger T, Itchaki G, et al
    Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity.
    Leuk Lymphoma. 2021;62:2921-2927.
    PubMed     Abstract available


    November 2021
  439. PRZESPOLEWSKI AC, Portwood S, Wang ES
    Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches.
    Leuk Lymphoma. 2021 Nov 25:1-10. doi: 10.1080/10428194.2021.1992614.
    PubMed     Abstract available


  440. PALMIERI R, Buccisano F, Arena V, Irno Consalvo MA, et al
    CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Nov 21:1-5. doi: 10.1080/10428194.2021.2005042.
    PubMed    


  441. KHANAL N, Shostrom V, Dhakal P, Upadhyay Banskota S, et al
    Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis.
    Leuk Lymphoma. 2021 Nov 17:1-7. doi: 10.1080/10428194.2021.2005046.
    PubMed     Abstract available


  442. YUE X, Hincapie AL, Li Y, Guo JJ, et al
    Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.
    Leuk Lymphoma. 2021 Nov 15:1-9. doi: 10.1080/10428194.2021.2002320.
    PubMed     Abstract available


  443. JADERSTEN M, Boriskina K, Lindholm C, Westrom S, et al
    Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 15:1-4. doi: 10.1080/10428194.2021.2002319.
    PubMed    


  444. HALPERN AB, Estey EH
    More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels.
    Leuk Lymphoma. 2021 Nov 8:1-4. doi: 10.1080/10428194.2021.1999446.
    PubMed    


  445. ZEIDAN AM, Qi CZ, Yang H, Garnham A, et al
    Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.
    Leuk Lymphoma. 2021 Nov 8:1-3. doi: 10.1080/10428194.2021.2001467.
    PubMed    


  446. DA CUNHA-BANG C, Kirkby NS, Friis-Hansen L, Niemann CU, et al
    Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Nov 2:1-3. doi: 10.1080/10428194.2021.1973673.
    PubMed    


  447. ARUMUGAM JR, Bommannan K, Radhakrishnan V, Sagar TG, et al
    Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Leuk Lymphoma. 2021 Nov 2:1-9. doi: 10.1080/10428194.2021.1992755.
    PubMed     Abstract available


  448. RIDGE SM, Whiteley AE, Yao H, Price TT, et al
    Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse.
    Leuk Lymphoma. 2021;62:2690-2702.
    PubMed     Abstract available


  449. SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
    Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
    Leuk Lymphoma. 2021;62:2716-2726.
    PubMed     Abstract available


  450. PATNAIK MM, Mughal TI, Brooks C, Lindsay R, et al
    Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.
    Leuk Lymphoma. 2021;62:2568-2586.
    PubMed     Abstract available


    October 2021
  451. ALDOSS I, Clark M, Marcucci G, Forman SJ, et al
    Donor derived leukemia in allogeneic transplantation.
    Leuk Lymphoma. 2021 Oct 29:1-8. doi: 10.1080/10428194.2021.1929966.
    PubMed     Abstract available


  452. REX MR, Williams R, Birsoy K, Ta Llman MS, et al
    Targeting mitochondrial metabolism in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Oct 27:1-8. doi: 10.1080/10428194.2021.1992759.
    PubMed     Abstract available


  453. GHIUZELI CM, Styblo M, Saunders J, Calabro A, et al
    The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
    Leuk Lymphoma. 2021 Oct 25:1-11. doi: 10.1080/10428194.2021.1978084.
    PubMed     Abstract available


  454. TONG WH
    Comment on 'asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly diagnosed acute lymphoblastic leukemia'.
    Leuk Lymphoma. 2021 Oct 22:1-2. doi: 10.1080/10428194.2021.1992760.
    PubMed    


  455. CHEN M, Fu M, Wang A, Wu X, et al
    Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.
    Leuk Lymphoma. 2021 Oct 21:1-9. doi: 10.1080/10428194.2021.1980214.
    PubMed     Abstract available


  456. GJAERDE LK, Rank CU, Andersen MK, Jakobsen LH, et al
    Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study.
    Leuk Lymphoma. 2021 Oct 21:1-10. doi: 10.1080/10428194.2021.1992620.
    PubMed     Abstract available


  457. RAMOS PEREZ JM, Patel KP, Loghavi S, Garcia-Manero G, et al
    Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
    Leuk Lymphoma. 2021 Oct 20:1-4. doi: 10.1080/10428194.2021.1992757.
    PubMed     Abstract available


  458. DOMENECH C, Plesa A, Tourette A, Bertrand Y, et al
    Prognostic impact of cN-III mRNA expression on overall survival and drug sensitivity in pediatric leukemia.
    Leuk Lymphoma. 2021 Oct 18:1-6. doi: 10.1080/10428194.2021.1992616.
    PubMed    


  459. LI S, Ji Y, Peng Y, Kota V, et al
    Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy.
    Leuk Lymphoma. 2021 Oct 13:1-11. doi: 10.1080/10428194.2021.1973669.
    PubMed     Abstract available


  460. COCHRANE T, Enrico A, Gomez-Almaguer D, Hadjiev E, et al
    Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
    Leuk Lymphoma. 2021 Oct 11:1-11. doi: 10.1080/10428194.2021.1986217.
    PubMed     Abstract available


  461. AGIUS R, Parviz M, Niemann CU
    Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-art.
    Leuk Lymphoma. 2021 Oct 6:1-14. doi: 10.1080/10428194.2021.1973672.
    PubMed     Abstract available


  462. XUE S, Zhang Y, Liu F, Huang W, et al
    Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation.
    Leuk Lymphoma. 2021 Oct 5:1-5. doi: 10.1080/10428194.2021.1984453.
    PubMed    


  463. NACHMIAS B, Rund D
    p53 in Acute Myeloid Leukemia-Still a significant other.
    Leuk Lymphoma. 2021 Oct 5:1-3. doi: 10.1080/10428194.2021.1988592.
    PubMed    


  464. LEE Y, Yun J, Jeong D, Ryu S, et al
    Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
    Leuk Lymphoma. 2021 Oct 1:1-10. doi: 10.1080/10428194.2021.1983568.
    PubMed     Abstract available


  465. SEYMOUR JF
    The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLL.
    Leuk Lymphoma. 2021;62:2299-2302.
    PubMed    


  466. ALHALLAK K, de la Puente P, Jeske A, Sun J, et al
    3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.
    Leuk Lymphoma. 2021;62:2457-2465.
    PubMed     Abstract available


  467. JACOBY MA, Finn L, Emadi A, Saba NS, et al
    Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).
    Leuk Lymphoma. 2021;62:2539-2542.
    PubMed    


  468. RAMAN I, Pasricha SR, Prince HM, Yannakou CK, et al
    Management of hydroxyurea resistant or intolerant polycythemia vera.
    Leuk Lymphoma. 2021;62:2310-2319.
    PubMed     Abstract available


  469. SHIMONY S, Yeshurun M, Wolach O, Ram R, et al
    Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.
    Leuk Lymphoma. 2021;62:2475-2481.
    PubMed     Abstract available


    September 2021
  470. VAN BESIEN K, Gomez-Arteaga A
    Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations.
    Leuk Lymphoma. 2021 Sep 29:1-4. doi: 10.1080/10428194.2021.1980787.
    PubMed    


  471. MALPICA L, Castro D, Enriquez DJ, Oviedo-Pecho R, et al
    An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2021 Sep 29:1-11. doi: 10.1080/10428194.2021.1984455.
    PubMed     Abstract available


  472. CHAJUWAN T, Kansuwan P, Kobbuaklee S, Chanswangphuwana C, et al
    Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984454.
    PubMed     Abstract available


  473. ALDERUCCIO JP, Lossos IS
    NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
    Leuk Lymphoma. 2021 Sep 29:1-12. doi: 10.1080/10428194.2021.1984452.
    PubMed     Abstract available


  474. STAHL M, Tallman MS, Goldberg AD
    Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey.
    Leuk Lymphoma. 2021 Sep 14:1-2. doi: 10.1080/10428194.2021.1929967.
    PubMed    


  475. PATEL SA, Lloyd MR, Cerny J, Shi Q, et al
    Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia.
    Leuk Lymphoma. 2021 Sep 9:1-13. doi: 10.1080/10428194.2021.1957869.
    PubMed     Abstract available


  476. BANKAR A, Lipton JH
    Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.
    Leuk Lymphoma. 2021 Sep 8:1-10. doi: 10.1080/10428194.2021.1971219.
    PubMed     Abstract available


  477. KHULLAR K, Plascak JJ, Parikh RR
    Acute lymphoblastic leukemia (ALL) in adults: disparities in treatment intervention based on access to treatment facility.
    Leuk Lymphoma. 2021 Sep 8:1-9. doi: 10.1080/10428194.2021.1975187.
    PubMed     Abstract available


  478. JACOBS JW, Ramaswamy R, States V, Reppucci J, et al
    Chronic myeloid leukemia with pure erythroid leukemia blast crisis.
    Leuk Lymphoma. 2021 Sep 6:1-5. doi: 10.1080/10428194.2021.1975191.
    PubMed     Abstract available


  479. XU DM, Yu WJ, Xie L, Zhang ZW, et al
    The diagnostic profile of rare acute myelomegakaryoblastic leukemia.
    Leuk Lymphoma. 2021 Sep 3:1-8. doi: 10.1080/10428194.2021.1955878.
    PubMed     Abstract available


  480. VENUGOPAL S, Maiti A, DiNardo CD, Qiao W, et al
    Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
    Leuk Lymphoma. 2021 Sep 3:1-5. doi: 10.1080/10428194.2021.1973675.
    PubMed    


  481. DUPUY H, Dussiau C, Bidet A, Sauvezie M, et al
    Looking for somatic mutations in UBA1 in patients with chronic myelomonocytic leukemia associated with systemic inflammation and autoimmune diseases.
    Leuk Lymphoma. 2021 Sep 3:1-3. doi: 10.1080/10428194.2021.1973674.
    PubMed    


  482. FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
    Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Leuk Lymphoma. 2021;62:2295-2297.
    PubMed    


  483. ELITZUR S, Frank S, Goshen-Lago T, Barzilai-Birenboim S, et al
    Long-term ovarian reserve and fertility outcomes in female survivors of childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021;62:2211-2218.
    PubMed     Abstract available


  484. DE CARVALHO AC, Ogawa CY Junior, De Camillis Rodrigues L, de Medeiros LS, et al
    Penicillium genus as a source for anti-leukemia compounds: an overview from 1984 to 2020.
    Leuk Lymphoma. 2021;62:2079-2093.
    PubMed     Abstract available


  485. PEPE S, Scalzulli E, Colafigli G, Di Prima A, et al
    Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience.
    Leuk Lymphoma. 2021;62:2261-2266.
    PubMed     Abstract available


  486. ARORA S, Vachhani P, Bachiashvili K, Jamy O, et al
    Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021;62:2292-2294.
    PubMed    


    August 2021
  487. HANSENNE A, Camboni A, Van Den Neste E, Bailly S, et al
    Richter transformation heralded by EBV reactivation during ibrutinib therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Aug 25:1-3. doi: 10.1080/10428194.2021.1964023.
    PubMed    


  488. PATEL SA, Dalela D, Fan AC, Lloyd MR, et al
    Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.
    Leuk Lymphoma. 2021 Aug 19:1-9. doi: 10.1080/10428194.2021.1966779.
    PubMed     Abstract available


  489. ZERBIT J, Tamburini J, Goldwirt L, Decroocq J, et al
    Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-4. doi: 10.1080/10428194.2021.1966787.
    PubMed    


  490. WANG J, Yang L, Dao FT, Wang YZ, et al
    Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-10. doi: 10.1080/10428194.2021.1966785.
    PubMed     Abstract available


  491. KIMBLE EL, Cassaday RD
    Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
    Leuk Lymphoma. 2021 Aug 17:1-15. doi: 10.1080/10428194.2021.1964022.
    PubMed     Abstract available


  492. SOREL N, Raimbault A, Brizard F, Depaire T, et al
    Identification and genetic characterization of a NUP98-HHEX molecular rearrangement in a pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 17:1-5. doi: 10.1080/10428194.2021.1966784.
    PubMed    


  493. MITROVIC M, Pantic N, Sabljic N, Vucic M, et al
    Acute leukemia and SARS-CoV-2 infection: clinical characteristics and risk factors for mortality.
    Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1964026.
    PubMed     Abstract available


  494. WOYACH J, Tedeschi A, Munir T, Siddiqi T, et al
    Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2021 Aug 13:1-5. doi: 10.1080/10428194.2021.1957871.
    PubMed    


  495. ABBAS HA, Reville PK, Geppner A, Rausch CR, et al
    Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.
    Leuk Lymphoma. 2021 Aug 12:1-9. doi: 10.1080/10428194.2021.1961235.
    PubMed     Abstract available


  496. NEE A, Lipton JH, Kim DDH
    Early prediction of stable MR(4.5) by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.
    Leuk Lymphoma. 2021 Aug 11:1-8. doi: 10.1080/10428194.2021.1961234.
    PubMed     Abstract available


  497. CORDOVA-SERRANO RD, Almanza-Huante E, Fernandez-Sanchez E, Hernandez-Alcantara A, et al
    Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry.
    Leuk Lymphoma. 2021 Aug 9:1-7. doi: 10.1080/10428194.2021.1957872.
    PubMed     Abstract available


  498. KUTTIKRISHNAN S, Prabhu KS, Khan AQ, Alali FQ, et al
    Thiostrepton inhibits growth and induces apoptosis by targeting FoxM1/SKP2/MTH1 axis in B-precursor acute lymphoblastic leukemia cells.
    Leuk Lymphoma. 2021 Aug 9:1-11. doi: 10.1080/10428194.2021.1957873.
    PubMed     Abstract available


  499. AL-HADAD SA, Al-Jadiry MF, Ghali HH, Al-Badri SAF, et al
    Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center.
    Leuk Lymphoma. 2021 Aug 6:1-10. doi: 10.1080/10428194.2021.1961237.
    PubMed     Abstract available


  500. YANADA M, Mizuno S, Yamasaki S, Harada K, et al
    Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.
    Leuk Lymphoma. 2021 Aug 4:1-9. doi: 10.1080/10428194.2021.1961242.
    PubMed     Abstract available


  501. COPPOLA PE, Broccoli A, Argnani L, Casadei B, et al
    Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases.
    Leuk Lymphoma. 2021 Aug 4:1-4. doi: 10.1080/10428194.2021.1961241.
    PubMed    


  502. RAMIREZ-LOPEZ A, Lazaro Del Campo P, Humala K, De la Cruz Benito B, et al
    Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak.
    Leuk Lymphoma. 2021;62:2034-2036.
    PubMed    


  503. ROSSO A, Juliusson G, Lorenz F, Lehmann S, et al
    Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
    Leuk Lymphoma. 2021;62:1973-1981.
    PubMed     Abstract available


  504. NAUR TMH, Jakobsen LH, Roug AS, El-Galaly TC, et al
    Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001-2016: a Danish nationwide cohort study.
    Leuk Lymphoma. 2021;62:2014-2017.
    PubMed    


    July 2021
  505. WAN CL, Zou JY, Qiao M, Yin J, et al
    Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
    Leuk Lymphoma. 2021 Jul 29:1-4. doi: 10.1080/10428194.2021.1957876.
    PubMed    


  506. KOUTROUMANI M, Laidou S, Kotta K, Stamatopoulos K, et al
    TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jul 29:1-4. doi: 10.1080/10428194.2021.1957870.
    PubMed    


  507. SWEET K, Bhatnagar B, Dohner H, Donnellan W, et al
    A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 29:1-12. doi: 10.1080/10428194.2021.1950706.
    PubMed     Abstract available


  508. EL HUSSEIN S, Wang W, Wang SA, Loghavi S, et al
    Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon.
    Leuk Lymphoma. 2021 Jul 24:1-4. doi: 10.1080/10428194.2021.1957878.
    PubMed    


  509. PALANQUES-PASTOR T, Megias-Vericat JE, Martinez P, Lopez Lorenzo JL, et al
    Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
    Leuk Lymphoma. 2021 Jul 22:1-11. doi: 10.1080/10428194.2021.1948031.
    PubMed     Abstract available


  510. WEBSTER JA, Yogarajah M, Zahurak M, Symons H, et al
    A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic
    Leuk Lymphoma. 2021 Jul 21:1-11. doi: 10.1080/10428194.2021.1948029.
    PubMed     Abstract available


  511. DUNN KA, Forbrigger Z, Connors J, Rahman M, et al
    Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Jul 19:1-12. doi: 10.1080/10428194.2021.1953006.
    PubMed     Abstract available


  512. BEYAN C
    Mean platelet volume may not be a predictive and prognostic marker in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 14:1. doi: 10.1080/10428194.2021.1953017.
    PubMed    


  513. GAO J, Fu L, Lu X, Sukhanova M, et al
    Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of TP53 mutation and genetic complexity.
    Leuk Lymphoma. 2021 Jul 14:1-4. doi: 10.1080/10428194.2021.1950710.
    PubMed    


  514. PAGNANO KB, Peralta EH, Navarro JR, David Salas LDR, et al
    COVID-19 in chronic myeloid leukemia patients in Latin America.
    Leuk Lymphoma. 2021 Jul 13:1-7. doi: 10.1080/10428194.2021.1950709.
    PubMed     Abstract available


  515. JIANG H, Liu XH, Kong J, Wang J, et al
    Interferon-alpha as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 1:1-8. doi: 10.1080/10428194.2021.1948027.
    PubMed     Abstract available


  516. JINDAL N, Lad DP, Malhotra P, Prakash G, et al
    Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL.
    Leuk Lymphoma. 2021;62:1674-1681.
    PubMed     Abstract available


  517. WITTMANN DAYAGI T, Sherman G, Bielorai B, Adam E, et al
    Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells.
    Leuk Lymphoma. 2021;62:1692-1701.
    PubMed     Abstract available


    June 2021
  518. STAHL M, Narendra V, Jee J, Derkach A, et al
    Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.
    Leuk Lymphoma. 2021 Jun 28:1-9. doi: 10.1080/10428194.2021.1885664.
    PubMed     Abstract available


  519. LEPRETRE S, Touboul C, Flinois A, Kutikova L, et al
    Quality of life in adults with acute lymphoblastic leukemia in France: results from a French cross-sectional study.
    Leuk Lymphoma. 2021 Jun 24:1-11. doi: 10.1080/10428194.2021.1941924.
    PubMed     Abstract available


  520. YOSHIMOTO G, Mori Y, Kato K, Odawara J, et al
    Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jun 23:1-10. doi: 10.1080/10428194.2021.1941937.
    PubMed     Abstract available


  521. SINGH J, Facey A, O'Malley F, Ryland GL, et al
    Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH.
    Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941935.
    PubMed    


  522. HADJIAGGELIDOU C, Douganiotis G, Tsirou K, Verrou E, et al
    A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941932.
    PubMed    


  523. RAMKISSOON LA, Buhlinger K, Nichols A, Coombs CC, et al
    Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1941928.
    PubMed    


  524. BOLUDA B, Martinez-Cuadron D, Algarra L, Cano I, et al
    Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
    Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1938031.
    PubMed     Abstract available


  525. CHIHARA D, Larson MC, Robinson DP, Thompson CA, et al
    Body mass index and survival of patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 14:1-8. doi: 10.1080/10428194.2021.1929956.
    PubMed     Abstract available


  526. KHAZAL S, Kebriaei P
    Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes.
    Leuk Lymphoma. 2021 Jun 3:1-14. doi: 10.1080/10428194.2021.1933475.
    PubMed     Abstract available


  527. STUBBINS RJ, Maksakov IA, Sanford DS, Rouhi A, et al
    Mitochondrial metabolism: powering new directions in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jun 1:1-11. doi: 10.1080/10428194.2021.1910685.
    PubMed     Abstract available


  528. BOULLAND ML, Vic S, Thonier F, Ganard M, et al
    Reliable IGHV status assessment by next generation sequencing in routine practice for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jun 1:1-4. doi: 10.1080/10428194.2021.1933476.
    PubMed    


  529. LADHA A, Hui G, Cheung E, Berube C, et al
    Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.
    Leuk Lymphoma. 2021;62:1510-1513.
    PubMed    


  530. SENAPATI J, Dhawan R, Aggarwal M, Kumar P, et al
    Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country.
    Leuk Lymphoma. 2021;62:1514-1517.
    PubMed    


  531. QU S, Jia Y, Wang H, Ai X, et al
    STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms.
    Leuk Lymphoma. 2021;62:1506-1509.
    PubMed    


    May 2021
  532. YURKIEWICZ IR, Coutre S, Ghesquieres H, Pastan I, et al
    Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.
    Leuk Lymphoma. 2021 May 25:1-3. doi: 10.1080/10428194.2021.1929959.
    PubMed    


  533. CUMBO C, Tota G, De Grassi A, Anelli L, et al
    RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia.
    Leuk Lymphoma. 2021 May 24:1-5. doi: 10.1080/10428194.2021.1929960.
    PubMed    


  534. SHARMA P, Rana S, Virk H, Sachdeva MUS, et al
    The frequency, hematological characteristics, and end-of induction residual disease in B-acute lymphoblastic leukemia with BCR-ABL1-like chimeric gene fusions in a high-risk cohort from India.
    Leuk Lymphoma. 2021 May 24:1-5. doi: 10.1080/10428194.2021.1929964.
    PubMed    


  535. JIN H, Zhu Y, Hong M, Wu Y, et al
    Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2021 May 24:1-10. doi: 10.1080/10428194.2021.1919660.
    PubMed     Abstract available


  536. BAZINET A, Rys RN, Barry A, Greenwood CMT, et al
    A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1919658.
    PubMed     Abstract available


  537. TIGLIOGLU M, Albayrak M, Dogan S, Yilmaz F, et al
    Mean platelet volume is a predictive and prognostic marker for patients with acute myeloid leukemia: a two-center retrospective analysis.
    Leuk Lymphoma. 2021 May 20:1-7. doi: 10.1080/10428194.2021.1929962.
    PubMed     Abstract available


  538. HANDL S, von Heydebrand F, Voelkl S, Oostendorp RAJ, et al
    Immune modulatory effects of Idelalisib in stromal cells of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 17:1-11. doi: 10.1080/10428194.2021.1927019.
    PubMed     Abstract available


  539. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.
    PubMed    


  540. KUROSAWA S, Kaito S, Uchida N, Fukuda T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.
    Leuk Lymphoma. 2021 May 12:1-7. doi: 10.1080/10428194.2021.1924374.
    PubMed     Abstract available


  541. DAVIDS MS, Telford C, Abhyankar S, Waweru C, et al
    Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 6:1-16. doi: 10.1080/10428194.2021.1913144.
    PubMed     Abstract available


  542. ADNAN-AWAD S, Kankainen M, Mustjoki S
    Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.
    Leuk Lymphoma. 2021 May 4:1-15. doi: 10.1080/10428194.2021.1894652.
    PubMed     Abstract available


  543. MARQUES-PIUBELLI ML, Schlette EJ, Khoury JD, Furqan F, et al
    Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
    Leuk Lymphoma. 2021;62:1129-1135.
    PubMed     Abstract available


    April 2021
  544. WALLWITZ J, Aigner P, Stoiber D
    Tumor suppressors in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Apr 30:1-11. doi: 10.1080/10428194.2021.1907372.
    PubMed     Abstract available


  545. WANG M, Wang R, Wang H, Chen C, et al
    Difference in gene mutation profile in patients with refractory/relapsed versus newly diagnosed acute myeloid leukemia based on targeted next-generation sequencing.
    Leuk Lymphoma. 2021 Apr 29:1-12. doi: 10.1080/10428194.2021.1919661.
    PubMed     Abstract available


  546. WANG N, Yuan L, Jing Y, Fan K, et al
    Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, TP53 deletion, and TP53 mutations.
    Leuk Lymphoma. 2021 Apr 27:1-9. doi: 10.1080/10428194.2021.1919663.
    PubMed     Abstract available


  547. REES MJ, Wu S, Mokoonlall M, Dix CHK, et al
    The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Apr 26:1-3. doi: 10.1080/10428194.2021.1919666.
    PubMed    


  548. ZHAN M, Chen ZB, Ding CC, Qu Q, et al
    Machine learning to predict high-dose methotrexate-related neutropenia and fever in children with B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Apr 26:1-12. doi: 10.1080/10428194.2021.1913140.
    PubMed     Abstract available


  549. GUPTA A, Gill S
    CAR-T cell persistence in the treatment of leukemia and lymphoma.
    Leuk Lymphoma. 2021 Apr 19:1-13. doi: 10.1080/10428194.2021.1913146.
    PubMed     Abstract available


  550. WALKER KL, Rinella SP, Hess NJ, Turicek DP, et al
    CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
    Leuk Lymphoma. 2021 Apr 11:1-11. doi: 10.1080/10428194.2021.1910684.
    PubMed     Abstract available


  551. FAZIO F, Quintini M, Carmosino I, Matteucci C, et al
    New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia.
    Leuk Lymphoma. 2021 Apr 9:1-4. doi: 10.1080/10428194.2021.1910689.
    PubMed    


  552. BENITEZ LL, Perissinotti AJ, Rausch CR, Klaus J, et al
    Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
    Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1907378.
    PubMed     Abstract available


  553. PASIC I, Paulson K, Dozois G, Schultz KR, et al
    Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data.
    Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1910688.
    PubMed     Abstract available


  554. HIDALGO-GOMEZ G, Palacio-Garcia C, Gallur L, Blanco A, et al
    Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis.
    Leuk Lymphoma. 2021 Apr 7:1-9. doi: 10.1080/10428194.2021.1907375.
    PubMed     Abstract available


  555. JOBSON D, McCormack CJ, Hiscutt E, Tam C, et al
    Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL.
    Leuk Lymphoma. 2021;62:992-994.
    PubMed    


  556. HARROP S, Polliack A, Tam CS
    Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond.
    Leuk Lymphoma. 2021;62:771-778.
    PubMed     Abstract available


  557. PACOUREAU L, De Menthon M, Boytchev I, Lazure T, et al
    Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies.
    Leuk Lymphoma. 2021;62:984-987.
    PubMed    


    March 2021
  558. CHEN NC, Borthakur G, Pemmaraju N
    Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms.
    Leuk Lymphoma. 2021;62:528-537.
    PubMed     Abstract available


    December 2020
  559. FOX TA, Carpenter B, Taj M, Perisoglou M, et al
    Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-6. doi: 10.1080/10428194.2020.1855346.
    PubMed    


    November 2020
  560. RASOR B, Dickerson T, Zhao Q, Elder P, et al
    Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
    Leuk Lymphoma. 2020 Nov 24:1-10. doi: 10.1080/10428194.2020.1849677.
    PubMed     Abstract available


  561. WANG T, Zhou B, Zhang J, Zhang X, et al
    Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
    Leuk Lymphoma. 2020 Nov 16:1-4. doi: 10.1080/10428194.2020.1846736.
    PubMed     Abstract available


  562. PAN W, Zhao X, Shi W, Jiang Z, et al
    Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020;61:2756-2759.
    PubMed    


    October 2020
  563. RODGERS TD, Williams AM, Baran A, Reagan PM, et al
    Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 25:1-8. doi: 10.1080/10428194.2020.1837796.
    PubMed     Abstract available


    August 2020
  564. NAGAHATA Y, Kondo T, Ono Y, Hiramoto N, et al
    High-dose cytarabine chemotherapy (>/=4 g/m(2)/day) before allogeneic hematopoietic stem cell transplantation for non-core-binding-factor AML in the first complete remission.
    Leuk Lymphoma. 2020 Aug 17:1-9. doi: 10.1080/10428194.2020.1805112.
    PubMed     Abstract available


    June 2020
  565. LU JP, Wang FX, Wen SP, Liu X, et al
    Haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in the treatment of T-lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-4. doi: 10.1080/10428194.2020.1775205.
    PubMed    


    January 2020
  566. RYLAND GL, Fox LC, Wootton V, Thompson ER, et al
    Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants.
    Leuk Lymphoma. 2020 Jan 16:1-3. doi: 10.1080/10428194.2019.1711075.
    PubMed    


    October 2019
  567. KUMAR P, Uppal M, Xiao W, Dogan A, et al
    Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications.
    Leuk Lymphoma. 2019 Oct 15:1-5. doi: 10.1080/10428194.2019.1675876.
    PubMed    


    September 2019
  568. WANG F, Liu T, Wang L, Gu Z, et al
    Unmanipulated haploidentical peripheral blood stem cell transplantation for patients with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission.
    Leuk Lymphoma. 2019 Sep 13:1-10. doi: 10.1080/10428194.2019.1660965.
    PubMed     Abstract available


    August 2019
  569. BALDUCCI E, Sanekli S, Hugues P, Soubeyrand M, et al
    Co-occurrence of BCR-ABL1 rearrangement and CALR mutation in a single leukemic stem cell: evidence that BCR-ABL1 oncogenic addiction prevails over CALR signaling.
    Leuk Lymphoma. 2019 Aug 29:1-4. doi: 10.1080/10428194.2019.1658101.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.